STIC Search Report
Biotech-Chem Library

USPTO

TO: Gerald R Ewoldt
Location: rem/3C83/3C70
Art Unit: 1644
Friday, October 20, 2006
Case Serial Number: 10/620621

From: John DiNatale
Location: Biotech-Chem Library
REM-1B65
Phone: (571)272-2557

john.dinatale@uspto.gov

Search Notes

Examiner Ewoldt,

See attached results.

If you have any questions about this search feel free to contact me at any time.

Thank you for using STIC search services!

John DiNatale
Technical Information Specialist
STIC Biotech/Chem Library
(571)272-2557

sira
Search and Information
Resources Administration

77452

10-755   204874

STIC-Biotech/ChemLib

From:
Sent: *CRFE*
To:
Subject:

Chan, Christina
Tuesday, October 17, 2006 5:38 PM
Ewoldt, Gerald; STIC-Biotech/ChemLib
RE: RUSH Seq Search for 10/620,621

Please rush. Thanks Chris

Chris Chan
TC 1600 New Hire Training Coordinator and SPE 1644
(571)-272-0841
Remsen, 3E89

-----Original Message-----
From: Ewoldt, Gerald
Sent: Tuesday, October 17, 2006 5:22 PM
To: Chan, Christina
Subject: RUSH Seq Search for 10/620,621

```
Christina,
Please authorize a RUSH Search.


STIC,
Please search SEQ ID NOS:1-10 including interference and send paper copy.



Thanks,

G.R. Ewoldt, Ph.D.
Primary Examiner
Remsen Bldg., 3C83
571-272-0843
```

1644
3C80

1 aa 20
2   20
3   20
4   19
5   18
6 aa 20
7 aa 20
8   20
9   19
10 aa 18

entered 10/18

ME

STIC SEARCH RESULTS FEEDBACK FORM

Biotech-Chem Library

Questions about the scope or the results of the search? Contact *the searcher or contact*:

Mary Hale, Information Branch Supervisor
571-272-2507 Remsen 1 A51

Voluntary Results Feedback Form

➤ *I am an examiner in Workgroup:* ☐   *Example: 1610*

➤ *Relevant prior art **found**, search results used as follows:*

        ☐ 102 rejection

        ☐ 103 rejection

        ☐ Cited as being of interest.

        ☐ Helped examiner better understand the invention.

        ☐ Helped examiner better understand the state of the art in their technology.

   Types of relevant prior art found:

        ☐ Foreign Patent(s)

        ☐ Non-Patent Literature
          (journal articles, conference proceedings, new product announcements etc.)

➤ *Relevant prior art **not found**:*

      ☐ Results verified the lack of relevant prior art (helped determine patentability).

      ☐ Results were not useful in determining patentability or understanding the invention.

Comments:

sira
Search and Information
Resources Administration

```
          GenCore version 5.1.9
          Copyright (c) 1993 - 2006 Biocceleration Ltd.

OM protein - protein search, using sw model

Run on:       October 18, 2006, 19:10:59 ; Search time 93.299 Seconds
                                           (without alignments)
                                           98.011 Million cell updates/sec

Title:             US-10-620-621-1
Perfect score:     85
Sequence:          1 TGYYXXXXQSPEKSLEWIG 20
Scoring table:     BLOSUM62
                   Gapop 10.0 , Gapext 0.5
Searched:          2589679 seqs, 45721629 residues

Total number of hits satisfying chosen parameters:        2589679

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
                 Maximum Match 100%
                 Listing first 45 summaries

Database :   A_Geneseq_8:*
              1: geneseqp1980s:*
              2: geneseqp1990s:*
              3: geneseqp2000s:*
              4: geneseqp2001s:*
              5: geneseqp2002s:*
              6: geneseqp2003as:*
              7: geneseqp2003bs:*
              8: geneseqp2004s:*
              9: geneseqp2005s:*
             10: geneseqp2006s:*
```

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Match Length	DB	ID	Description
1	80	94.1	20	2	AAW05029	Aaw05029 Synthetic
2	80	94.1	20	8	ADR14727	Adr14727 Amino aci
3	79	92.9	20	2	AAW05034	Aaw05034 Synthetic
4	79	92.9	20	5	AAE27944	Aae27944 Murine 5G
5	79	92.9	20	8	ADF70140	Adf70140 Anti-idio
6	79	92.9	20	8	ADR14717	Adr14717 Synthetic
7	79	92.9	470	8	ADM72027	Adm72027 Chimeric
8	79	92.9	470	10	AEF50993	Aef50993 Variable
9	71	83.5	255	5	ABP45615	Abp45615 Human BLy
10	71	83.5	255	7	ADG96442	Adg96442 Single ch
11	71	83.5	255	9	AED78495	Aed78495 Human B L
12	71	83.5	467	9	ADZ51037	Adz51037 Amino aci
13	71	83.5	467	9	ADZ51043	Adz51043 Amino aci
14	70	82.4	97	7	ADD28121	Add28121 Lymphoma
15	68	80.0	672	6	ABP58454	Abp58454 Engineere
16	68	80.0	672	10	AEF80925	Aef80925 Staphyloc
17	65	76.5	129	5	AAU81275	Aau81275 Human trk
18	64	75.3	123	6	ABR55799	Abr55799 Heavy cha
19	64	75.3	123	6	ABR55823	Abr55823 Heavy cha
20	64	75.3	124	9	ADY96947	Ady96947 Human imm
21	64	75.3	125	9	ADZ41992	Adz41992 Ig H chai
22	64	75.3	255	5	ABP45631	Abp45631 Human BLy
23	64	75.3	255	7	ADG96458	Adg96458 Single ch
24	64	75.3	255	9	AED78511	Aed78511 Human B L
25	63	74.1	93	3	AAY64660	Aay64660 Human 5'
26	63	74.1	93	8	ADU72224	Adu72224 Signal pe
27	63	74.1	93	9	ADZ73215	Adz73215 Human inc
28	63	74.1	97	7	ADD28117	Add28117 Lymphoma
29	63	74.1	114	4	AAR79244	Aar79244 Heavy cha
30	63	74.1	114	9	AAB50793	Aab50793 Murine an
31	63	74.1	115	4	AEA34944	Aea34944 Human ant
32	63	74.1	115	5	AEB17185	Aeb17185 EphA2-spe
33	63	74.1	115	5	AEA42985	Aea42985 EphA2 ant
34	63	74.1	115	10	AEF10097	Aef10097 Mouse-hum
35	63	74.1	115	10	AEF10112	Aef10112 Mouse-hum
36	63	74.1	121	4	AAE03752	Aae03752 Murine PS
37	63	74.1	121	7	ADH44153	Adh44153 Human ant
38	63	74.1	121	9	AEB21865	Aeb21865 Human DC-
39	63	74.1	121	9	AEB21868	Aeb21868 Human DC-
40	63	74.1	121	9	AEB21864	Aeb21864 Human DC-
41	63	74.1	121	9	AEB21869	Aeb21869 Human DC-
42	63	74.1	121	9	AEB21863	Aeb21863 Human DC-
43	63	74.1	124	9	AAY87655	Aay87655 Murine PI
44	63	74.1	136	6	ABU08927	Abu08927 Mouse amy
45	63	74.1	140	3	AAY64689	Aay64689 Human 5'

ALIGNMENTS

```
RESULT 1
AAW05029
ID   AAW05029 standard; peptide; 20 AA.
XX
AC   AAW05029;
XX
DT   29-MAY-1997  (first entry)
XX
DE   Synthetic peptide for treating systemic lupus erythematosus.
XX
KW   SLE; systemic lupus erythematosus; autoimmune disease; monoclonal;
KW   anti-DNA antibody; CDR; complementarity determining region; 16/6 Id;
KW   idiotype; nuclear antigen.
XX
OS   Synthetic.
XX
FH   Key                 Location/Qualifiers
FT   Misc-difference     5
FT                       /label= Met, Ala, Val
FT   Misc-difference     6
FT                       /label= Gln, Asp, Glu, Arg
FT   Misc-difference     7
FT                       /label= Trp, Ala
FT   Misc-difference     8
FT                       /label= Val, Ser
FT   Misc-difference     10
FT                       /label= Lys, Glu, Ala
XX
PN   WO9630057-A1.
XX
PD   03-OCT-1996.
XX
PF   27-MAR-1996;   96WO-US004206.
XX
PR   28-MAR-1995;   95IL-00113159.
XX
PA   (YEDA ) YEDA RES & DEV CO LTD.
PA   (RYCU/) RYCUS A.
XX
PI   Mozes E, Waisman A;
XX
DR   WPI; 1996-455014/45.
XX
PT   New synthetic peptide(s) for treating systemic lupus erythematosus -
PT   based on complementarity determining region of pathogenic anti-DNA
PT   monoclonal antibody that induces SLE-like disease in mice.
```

XX
PS   Claim 3; Page 36; 51pp; English.
XX
CC   AAW05029-W05038 are synthetic peptides based on the complementarity-
CC   determining region (CDR) of the heavy or light chain of a pathogenic 16/6
CC   Id anti-DNA monoclonal antibody (MAb), that induces a systemic lupus
CC   erythematosus (SLE)-like disease in mice. The peptides and their
CC   derivatives are used for treating SLE. The peptides inhibit or suppress
CC   specific antigen responses of SLE patients without affecting all other
CC   immune responses
XX
SQ   Sequence 20 AA;

Query Match   94.1%;   Score 80;   DB 2;   Length 20;
Best Local Similarity   100.0%;   Pred. No. 6.9e-07;
Matches   20;   Conservative   0;   Mismatches   0;   Indels   0;   Gaps   0;

Qy   1 TGYYXXXXQSPEKSLEWIG 20
       ||||||||||||||||||||
Db   1 TGYYXXXXQSPEKSLEWIG 20

RESULT 2
ADR14727
ID   ADR14727 standard; peptide; 20 AA.
XX
AC   ADR14727;
XX
DT   21-OCT-2004 (first entry)
XX
DE   Amino acid sequence of a peptide used to treat SLE.
XX
KW   complementarity determining region; CDR; heavy chain; light chain;
KW   monoclonal anti-DNA idiotype antibody; 16/6 Id antibody;
KW   anti-DNA antibody; induces systemic lupus erythematosus; SLE.
XX
OS   Synthetic.
XX
FH   Key   Location/Qualifiers
FT   Misc-difference 5
FT   /label= Met, Ala, Val
FT   Misc-difference 6
FT   /label= Gln, Asp, Glu, Arg
FT   Misc-difference 7
FT   /label= Trp, Ala
FT   Misc-difference 8
FT   /label= Val, Ser
FT   Misc-difference 9
FT   /label= Lys, Glu, Ala
XX
PN   WO2004064787-A2.
XX
PD   05-AUG-2004.
XX
PF   14-JAN-2004; 2004WO-US000948.
XX
PR   14-JAN-2003; 2003US-0439918P.
XX
PA   (TEVA-) TEVA PHARM IND LTD.
PA   (TEVA-) TEVA PHARM USA INC.
XX
PI   Cohen-Vered S, Naftali E, Weinstein V, Gilbert A, Klinger E;
XX
DR   WPI; 2004-580636/56.
XX
PT   Pharmaceutical composition for treating systemic lupus erythematosus
PT   (SLE), has salt of peptide corresponding to complementarity-determining
PT   region of heavy/light chain of anti-DNA 16/6 Id antibody that induces
PT   immune response to SLE.
XX
PS   Claim 1; SEQ ID NO 11; 132pp; English.
XX
CC   The specification describes a pharmaceutical composition, comprising a

CC   salt of a peptide with 12-30 consecutive amino acids having a sequence
CC   corresponding to an amino acid sequence found within complementarity-
CC   determining region (CDR) of the heavy or light chain of the human
CC   monoclonal anti-DNA 16/6 idiotype (16/6 Id) antibody, or a heavy or light
CC   chain of a pathogenic anti-DNA monoclonal antibody that induces systemic
CC   lupus erythematosus (SLE)-like disease response in mice. The composition
CC   is useful for treating SLE and for alleviating symptoms of SLE in a human
CC   subject. The present sequence represents a peptide which is used in
CC   pharmaceutical compositions of the invention.
XX
SQ   Sequence 20 AA;

Query Match   94.1%;   Score 80;   DB 8;   Length 20;
Best Local Similarity   100.0%;   Pred. No. 6.9e-07;
Matches   20;   Conservative   0;   Mismatches   0;   Indels   0;   Gaps   0;

Qy   1 TGYYXXXXQSPEKSLEWIG 20
       ||||||||||||||||||||
Db   1 TGYYXXXXQSPEKSLEWIG 20

RESULT 3
AAW05034
ID   AAW05034 standard; peptide; 20 AA.
XX
AC   AAW05034;
XX
DT   29-MAY-1997 (first entry)
XX
DE   Synthetic peptide for treating systemic lupus erythematosus.
XX
KW   SLE; systemic lupus erythematosus; autoimmune disease; monoclonal;
KW   anti-DNA antibody; CDR; complementarity determining region; 16/6 Id;
KW   idiotype; nuclear antigen.
XX
OS   Synthetic.
XX
PN   WO9630057-A1.
XX
PD   03-OCT-1996.
XX
PF   27-MAR-1996;   96WO-US004206.
XX
PR   28-MAR-1995;   95IL-00113159.
XX
PA   (YEDA) YEDA RES & DEV CO LTD.
PA   (RYCU/) RYCU A.
XX
PI   Mozes E, Waisman A;
XX
DR   WPI; 1996-455014/45.
XX
PT   New synthetic peptide(s) for treating systemic lupus erythematosus -
PT   based on complementarity determining region of pathogenic anti-DNA
PT   monoclonal antibody that induces SLE-like disease in mice.
XX
PS   Claim 4; Page 37; 51pp; English.
XX
CC   AAW05029-W05038 are synthetic peptides based on the complementarity-
CC   determining region (CDR) of the heavy or light chain of a pathogenic 16/6
CC   Id anti-DNA monoclonal antibody (MAb), that induces a systemic lupus
CC   erythematosus (SLE)-like disease in mice. The peptides and their
CC   derivatives are used for treating SLE. The peptides inhibit or suppress
CC   specific antigen responses of SLE patients without affecting all other
CC   immune responses
XX
SQ   Sequence 20 AA;

Query Match   92.9%;   Score 79;   DB 2;   Length 20;
Best Local Similarity   75.0%;   Pred. No. 1e-06;
Matches   15;   Conservative   0;   Mismatches   0;   Indels   5;   Gaps   0;

Qy   1 TGYYXXXXQSPEKSLEWIG 20

Db ||| ||||||||||
            1 TGYYMQWVKQSPEKSLEWIG 20

RESULT 4
AAE27944
ID   AAE27944 standard; peptide; 20 AA.
XX
AC   AAE27944;
XX
DT   27-DEC-2002 (first entry)
XX
DE   Murine 5G12 mAb VH chain CDR1 based peptide.
XX
KW   Complementarity-determining region; CDR; variable heavy chain; VH; VL;
KW   variable light chain; SLE-associated response; immunosuppressive; SLE;
KW   systemic lupus erythematosus; dermatological; therapy; antiinflammatory;
KW   mouse.
XX
OS   Mus sp.
XX
PN   WO200267848-A2.
XX
PD   06-SEP-2002.
XX
PF   26-FEB-2002; 2002WO-IL000148.
XX
PR   26-FEB-2001; 2001IL-00141647.
XX
PA   (YEDA) YEDA RES & DEV CO LTD.
XX
PI   Mozes E;
XX
DR   WPI; 2002-698624/75.
XX
PT   New synthetic peptide useful for treating and ameliorating the clinical
PT   manifestations of systemic lupus erythematosus (SLE) by modulating SLE-
PT   associated responses.
XX
PS   Example 1; Page 4; 120pp; English.
XX
CC   The invention relates to a synthetic peptide selected from a peptide of
CC   12-30 amino acid residues with a sequence of, or found within, a
CC   complementarity-determining region (CDR) on the variable heavy (VH) or
CC   light (VL) chain of human monoclonal anti-DNA 16/6Id antibody (hCDR). The
CC   composition comprising the peptide is useful for the treatment of
CC   systemic lupus erythematosus (SLE) and amelioration of the clinical
CC   manifestations of the disease, particularly by modulating SLE-associated
CC   responses. The present sequence is murine mAb VH chain CDR peptide
XX
SQ   Sequence 20 AA;

Query Match   92.9%; Score 79; DB 5; Length 20;
Best Local Similarity   75.0%; Pred. No. 1e-06;
Matches 15; Conservative   0; Mismatches   5; Indels   0; Gaps   0;

Qy   1 TGYXXXXQSPEKSLEWIG 20
              |||| |||||||||||||
Db   1 TGYYMQWVKQSPEKSLEWIG 20

RESULT 5
ADF70140
ID   ADF70140 standard; peptide; 20 AA.
XX
AC   ADF70140;
XX
DT   26-FEB-2004 (first entry)
XX
DE   Anti-idiotype antibody related peptide.
XX
KW   autoimmune disease-associated autoantibody; autoantibody;
KW   autoimmune disease; immunoglobulin; anti-idiotypic antibody;

KW   immunosuppressive; antiinflammatory; dermatological; muscular;
KW   neuroprotective; CNS; anti-HIV; nootropic; neuroleptic; antithyroid;
KW   thyromimetic; antidiabetic; anabolic; hypertensive; endocrine;
KW   antipsoriatic; hepatotropic; virucide; antianaemic; haemostatic;
KW   gastrointestinal; antiulcer; antiinfertility; antirheumatic;
KW   antiarthritic; nephrotropic; antiarteriosclerotic; cardiant;
KW   ophthalmological; uropathic; antipyretic; vaccine.
XX
OS   Synthetic.
XX
PN   WO200309868-A2.
XX
PD   04-DEC-2003.
XX
PF   22-MAY-2003; 2003WO-IL000424.
XX
PR   28-MAY-2002; 2002US-0383136P.
XX
PA   (OMRI-) OMRIX BIOPHARMACEUTICALS INC.
XX
PI   Nur I, Shoenfeld Y;
XX
DR   WPI; 2004-042771/04.
XX
PT   Identifying molecules, which mimic an idiotype of an autoimmune disease-
PT   associated autoantibody, useful for treating an autoimmune disease, e.g.
PT   myasthenia gravis, comprises the use of immunoglobulins purified from
PT   pooled plasma.
XX
PS   Example 3; Page 12; 43pp; English.
XX
CC   The present invention describes a method (M1) for identifying molecules
CC   (I) which mimic an idiotype of an autoimmune disease-associated
CC   autoantibody (autoantibodies). M1 comprises purifying autoantibodies from
CC   sera of one or more patients afflicted with the autoimmune disease,
CC   binding the autoantibodies to a solid phase to form an affinity matrix,
CC   contacting pooled plasma or B cells comprising immunoglobulins with the
CC   affinity matrix followed by removal of unbound plasma components, eluting
CC   bound immunoglobulins, being anti-idiotypic antibodies (anti-id) to
CC   autoantibodies, from the matrix, providing a molecular library comprising
CC   several molecule members, and contacting the anti-id with the molecular
CC   library and isolating the bound molecules, which are bound by the anti-
CC   Id, the bound molecules being molecules that mimic an idiotype of
CC   autoantibodies. (I) have immunosuppressive, antiinflammatory,
CC   dermatological, muscular, neuroprotective, CNS, anti-HIV, nootropic,
CC   neuroleptic, antithyroid, thyromimetic, antidiabetic, anabolic,
CC   hypertensive, endocrine, antipsoriatic, hepatotropic, virucide,
CC   antianaemic, haemostatic, gastrointestinal, antiulcer, antiinfertility,
CC   antirheumatic, antiarthritic, nephrotropic, antiarteriosclerotic,
CC   cardiant, ophthalmological, uropathic and antipyretic activities, and can
CC   be used in vaccines. The molecules (I), anti-Id and pharmaceutical
CC   compositions of the present invention can be used for treating a patient
CC   afflicted with an autoimmune disease. The molecules (I) are also useful
CC   for screening chemical compounds for their potential use in treating an
CC   autoimmune disease. The present sequence is given in the exemplification
CC   of the present invention.
XX
SQ   Sequence 20 AA;

Query Match   92.9%; Score 79; DB 8; Length 20;
Best Local Similarity   75.0%; Pred. No. 1e-06;
Matches 15; Conservative   0; Mismatches   5; Indels   0; Gaps   0;

Qy   1 TGYXXXXQSPEKSLEWIG 20
              |||| |||||||||||||
Db   1 TGYYMQWVKQSPEKSLEWIG 20

RESULT 6
ADR14717
ID   ADR14717 standard; peptide; 20 AA.
XX
AC   ADR14717;

```
XX
DT   21-OCT-2004  (first entry)
XX
DE   Synthetic peptide based on VH CDR1 of monoclonal antibody 5G12.
XX
KW   complementarity determining region; CDR; heavy chain; light chain;
KW   monoclonal anti-DNA 16/6 idiotype antibody; 16/6 Id antibody;
KW   anti-DNA antibody; induces systemic lupus erythematosus; SLE;
KW   antibody 5G12.
XX
OS   Synthetic.
XX
PN   WO2004064787-A2.
XX
PD   05-AUG-2004.
XX
PF   14-JAN-2004; 2004WO-US000948.
XX
PR   14-JAN-2003; 2003US-0439918P.
XX
PA   (TEVA-) TEVA PHARM IND LTD.
PA   (TEVA-) TEVA PHARM USA INC.
XX
PI   Cohen-Vered S, Naftali E, Weinstein V, Gilbert A, Klinger E;
XX
DR   WPI; 2004-580636/56.
XX
PT   Pharmaceutical composition for treating systemic lupus erythematosus
PT   (SLE), has salt of peptide corresponding to complementarity-determining
PT   region of heavy/light chain of anti-DNA 16/6 Id antibody that induces
PT   immune response to SLE.
XX
PS   Claim 3; SEQ ID NO 1; 132pp; English.
XX
CC   The specification describes a pharmaceutical composition, comprising a
CC   salt of a peptide with 12-30 consecutive amino acids having a sequence
CC   corresponding to an amino acid sequence found within complementarity-
CC   determining region (CDR) of the heavy or light chain of the human
CC   monoclonal anti-DNA 16/6 idiotype (16/6 Id) antibody, or a heavy or light
CC   chain of a pathogenic anti-DNA monoclonal antibody that induces systemic
CC   lupus erythematosus (SLE)-like disease response in mice. The composition
CC   is useful for treating SLE and for alleviating symptoms of SLE in a human
CC   subject. The present sequence represents a peptide based on CDR1 of the
CC   heavy chain V region of monoclonal antibody.5G12. The 5G12 monoclonal
CC   antibody was isolated from mice with experimental SLE, and was shown to
CC   bind DNA and bear the 16/6 Id. The present peptide is used in
CC   pharmaceutical compositions of the invention.
XX
SQ   Sequence 20 AA;
XX
Query Match             92.9%;  Score 79;  DB 8;  Length 20;
Best Local Similarity   75.0%;  Pred. No. 1e-06;
Matches   15;  Conservative   0;--Mismatches   5;  Indels   0;  Gaps   0;

Qy    1 TGYYXXXXQSPEKSLEWIG 20
          ||||   ||||||||||
Db    1 TGYYMQWVKQSPEKSLEWIG 20

RESULT 7
ADM72027
ID   ADM72027 standard; protein; 470 AA.
XX
AC   ADM72027;
XX
DT   03-JUN-2004  (first entry)
XX
DE   Chimeric mouse-human antibody M1E07 heavy chain.
XX
KW   GPC3; glypican 3; anti-GPC3 antibody; cell disruption; anti-cancer;
KW   cytostatic; M1E07.
XX
OS   Mus sp.
```

```
OS   Homo sapiens.
OS   Chimeric.
XX
PN   WO2004022739-A1.
XX
PD   18-MAR-2004.
XX
PF   04-SEP-2003; 2003WO-JP011318.
XX
PR   04-SEP-2002; 2002WO-JP008999.
XX
PA   (CHUS ) CHUGAI SEIYAKU KK.
XX
PI   Aburatani H, Midorikawa Y, Nakano K, Ohizumi I, Ito Y, Tokita S;
XX
DR   WPI; 2004-269573/25.
DR   N-PSDB; ADM72026.
XX
PT   Antibody against the N terminus of glypican 3 (GPC3) causes cell
PT   disruption and is useful as an anticancer agent.
XX
PS   Example 4; SEQ ID NO 12; 122pp; Japanese.
XX
CC   The invention relates to an antibody against the N terminus of glypican 3
CC   (GPC3). The antibody can be used for causing cell disruption and can be
CC   uses as an anti-cancer agent. The present sequence represents a chimeric
CC   mouse-human antibody M1E07 heavy chain.
XX
SQ   Sequence 470 AA;
XX
Query Match             92.9%;  Score 79;  DB 8;  Length 470;
Best Local Similarity   75.0%;  Pred. No. 3.3e-05;
Matches   15;  Conservative   0;  Mismatches   5;  Indels   0;  Gaps   0;

Qy    1 TGYYXXXXQSPEKSLEWIG 20
          ||||   ||||||||
Db   49 TGYYMHWVKQSPEKSLEWIG 68

RESULT 8
AEF50993
ID   AEF50993 standard; protein; 470 AA.
XX
AC   AEF50993;
XX
DT   23-MAR-2006  (first entry)
XX
DE   Variable region of anti-glypican-3 antibody, SEQ ID NO:24.
XX
KW   humanized antibody; antibody engineering; cell growth; cancer;
KW   cytostatic; neoplasm; hepatocellular carcinoma; gastointestinal disease;
KW   diagnosis; glypican-3; GPC3.
XX
OS   Mus musculus.
XX
PN   WO2006006693-A1.
XX
PD   19-JAN-2006.
XX
PF   08-JUL-2005; 2005WO-JP013103.
XX
PR   09-JUL-2004; 2004JP-00203637.
XX
PA   (CHUS ) CHUGAI SEIYAKU KK.
XX
PI   Nakano K, Yoshino T, Nezu J, Tsunoda H, Igawa T, Konishi H;
PI   Tanaka M, Sugo I, Kawai S, Ishiguro T, Kinoshita Y;
XX
DR   WPI; 2006-110188/11.
XX
PT   Novel anti-glypican 3 antibody having high complement dependent and
PT   antibody dependent cell-mediated cytotoxicity activity with respect to
PT   cell expressing glypican 3, useful as anticancer agent and as cell growth
```

PT inhibitor.
XX
PS Disclosure; SEQ ID NO 24; 184pp; Japanese.
XX
CC The new invention relates to an anti-glypican 3 (GPC3) antibody (A1)
CC comprising a heavy chain variable region having CDR1, CDR2 and CDR3 and a
CC light chain variable region having CDR1, CDR2 and CDR3. The antibody
CC comprises complementary determining regions (CDRs) of amino acid
CC sequence selected from a number of sequences fully defined in the
CC specification. The antibody may be humanized. Also described is an
CC antibody (A2) having an activity equivalent to (A1) and having a sequence
CC comprising one or several amino acid substitutions, deletions, additions
CC and/or insertions in the sequence of (A1); polynucleotide (N1) encoding
CC the heavy-chain variable region or light-chain variable region of (A1);
CC cell growth inhibitor (I) comprising (A1) as an active ingredient;
CC anticancer agent (II), comprising (A1) as an active ingredient; and
CC peptide (P1) having an amino acid sequence comprising amino acid residues
CC 524-563, 537-563, 544-553 or 546-551 of glypican 3. (I) is useful as a
CC cell growth inhibitor. (II) is useful as an anticancer, preferably useful
CC for treating hepatoma. (I) is useful as an anticancer agent and as a cell
CC growth inhibitor. (I) is useful for diagnosing cancer. (A1) has CDC and
CC ADCC activity. The present sequence is a variable region of a murine anti
CC -glypican-3 antibody.
XX
SQ Sequence 470 AA;
XX
Query Match   92.9%; Score 79; DB 10; Length 470;
Best Local Similarity   75.0%; Pred. No. 3.3e-05;
Matches 15; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Qy   1 TGYYXXXXQSPEKSLEWIG 20
               ||| ||||||||||||
Db   49 TGYYMHWVKQSPEKSLEWIG 68

RESULT 9
ABP45615
ID ABP45615 standard; protein; 255 AA.
XX
AC ABP45615;
XX
DT 19-AUG-2002 (first entry)
XX
DE Human BLyS binding scFv SEQ ID 1626.
XX
KW BLyS; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
KW tumour necrosis factor; B cell proliferation; B cell differentiation;
KW immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
KW antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
KW systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
KW common variable immunodeficiency; acquired immunodeficiency syndrome.
XX
OS Homo sapiens.
XX
PN WO20202641-A1.
XX
PD 10-JAN-2002.
XX
PF 15-JUN-2001; 2001WO-US019110.
XX
PR 16-JUN-2000; 2000US-0212210P.
PR 17-OCT-2000; 2000US-0240816P.
PR 16-MAR-2001; 2001US-0276248P.
PR 21-MAR-2001; 2001US-0277379P.
PR 25-MAY-2001; 2001US-0293499P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
PA (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
XX
PI Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
XX
DR WPI; 2002-114799/15.
XX

PT Antibodies against B Lymphocyte Stimulating polypeptides, useful for the
PT diagnosis and treatment of cancers and immune disorders.
XX
PS Claim 1; Page 2343-2344; 3148pp; English.
XX
CC This invention describes novel antibodies that immunospecifically bind to
CC B Lymphocyte Stimulator (BLyS) polypeptides. BLyS is a member of the
CC tumour necrosis factor (TNF) super family and induces B cell
CC proliferation and differentiation. The antibodies of the invention have
CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
CC antirheumatic and antiAIDS activity and can be used in vaccines to
CC inhibit the expression and activity of BLyS. The antibodies bind to BLyS
CC and so may be used to detect and quantitate the presence of BLyS in
CC biological samples and may be used in this way to diagnose disease
CC associated with aberrant expression of BLyS. They may also be
CC administered to treat diseases associated with aberrant BLyS expression
CC and activity such as cancer, immune, and autoimmune disorders and
CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
CC the antibodies and fragments of the antibodies described in the method of
CC the invention
XX
SQ Sequence 255 AA;
XX
Query Match   83.5%; Score 71; DB 5; Length 255;
Best Local Similarity   65.0%; Pred. No. 0.00045;
Matches 13; Conservative 1; Mismatches 6; Indels 0; Gaps 0;

Qy   1 TGYYXXXXQSPEKSLEWIG 20
               :||| |||||||||||
Db   30 SGYYWSWVRQSPEKGLEWIG 49

RESULT 10
ADG96442
ID ADG96442 standard; protein; 255 AA.
XX
AC ADG96442;
XX
DT 11-MAR-2004 (first entry)
XX
DE Single chain antibody that immunospecifically binds BLyS SeqID 1626.
XX
KW antibody; B lymphocyte stimulator; BLyS; tumour necrosis factor;
KW B cell proliferation; differentiation; scFv; myasthenia gravis;
KW multiple sclerosis; asthma; rheumatoid arthritis; AIDS; leukaemia;
KW carcinoma; lymphoma; antirheumatic; antiarthritic; neuroprotective;
KW antiinflammatory; antiasthmatic; antiallergic; cytostatic.
XX
OS Unidentified.
XX
PN WO200305979-A2.
XX
PD 10-JUL-2003.
XX
PF 14-NOV-2002; 2002WO-US036496.
XX
PR 16-NOV-2001; 2001US-0331469P.
PR 19-DEC-2001; 2001US-0340817P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Ruben SM, Barash SC, Choi GH, Vaughan TJ, Hilbert D;
XX
DR WPI; 2003-505530/47.
XX
PT Novel antibody that immunospecifically binds to a B lymphocyte stimulator
PT (BLys), useful for detecting and treating diseases or disorders e.g.
PT rheumatoid arthritis, asthma and leukemia.
XX
PS Example 1; SEQ ID NO 1626; 394pp; English.
XX

CC This invention relates to novel antibodies that immunospecifically bind
CC to B lymphocyte stimulator (BLyS). The BLyS gene has been mapped to
CC chromosome 13q34 and encodes a protein that is a member of the tumour
CC necrosis factor superfamily and induces both in vivo and in vitro B cell
CC proliferation and differentiation. Specifically, it refers to single
CC chain antibody molecules (scFvs) derived, preferably, from the variable
CC heavy CDR3 region that immunospecifically bind to a polypeptide, or
CC fragment thereof, of either human, murine, rat or monkey BLyS. The
CC present invention refers to the use of such antibodies in various methods
CC for the detection, diagnosis and prognosis of diseases related to the
CC aberrant expression or inappropriate function of BLyS or its receptor. As
CC such, these compositions are useful for identifying immune disorders
CC including myasthenia gravis and multiple sclerosis, inflammatory
CC disorders e.g. asthma and rheumatoid arthritis, infectious diseases such
CC as AIDS and proliferative disorders including leukaemia, carcinoma and
CC lymphoma. Accordingly, they can be described as exhibiting various
CC activities such as antirheumatic, antiarthritic, neuroprotective,
CC antiinflammatory, antiasthmatic, antiallergic and cytostatic. This
CC polypeptide sequence is a single chain antibody that binds BLyS of the
CC invention. NOTE:The sequence data for this patent did not form part of
CC the printed specification, but was obtained in electronic format
CC directly from WIPO at ftp.wipo.int/pub/published pct_sequences.
XX
SQ Sequence 255 AA;

Query Match 83.5%; Score 71; DB 7; Length 255;
Best Local Similarity 65.0%; Pred. No. 0.00045;
Matches 13; Conservative 1; Mismatches 6; Indels 0; Gaps 0;

Qy 1 TGYYXXXXQSPEKSLEWIG 20
        :||| |||||| ||||
Db 30 SGYYWSWVRQSPEKGLEWIG 49

RESULT 11
AED78495
ID AED78495 standard; protein; 255 AA.
XX
AC AED78495;
XX
DT 12-JAN-2006 (first entry)
XX
DE Human B Lymphocyte binding scFv fragment protein, SEQ ID 1626.
XX
KW Antiinflammatory; Dermatological; Immunosuppressive; Antirheumatic;
KW Antiarthritic; Neuroprotective; Muscular-Gen.; Antiasthmatic;
KW Antiallergic; Antimicrobial; Anti-HIV; Cytostatic; B-lymphocyte;
KW antibody; autoimmune disease; b-cell lymphoma;
KW systemic lupus erythematosus; rheumatoid arthritis; immune disorder;
KW inflammation; infectious disease; hyperproliferation.
XX
OS Homo sapiens.
XX
PN US200525532-A1.
XX
PD 17-NOV-2005.
XX
PF 10-FEB-2005; 2005US-00054515.
XX
PR 16-JUN-2000; 2000US-0212210P.
PR 17-OCT-2000; 2000US-0240816P.
PR 16-MAR-2001; 2001US-0276248P.
PR 21-MAR-2001; 2001US-0277379P.
PR 25-MAY-2001; 2001US-0293499P.
PR 15-JUN-2001; 2001US-00880748.
PR 16-NOV-2001; 2001US-0331469P.
PR 19-DEC-2001; 2001US-0340817P.
PR 14-NOV-2002; 2002US-00293418.
PR 11-FEB-2004; 2004US-0543296P.
PR 18-JUN-2004; 2004US-0580347P.
XX
PA (RUBE/) RUBEN S M.
PA (BARA/) BARASH S C.

PA (CHOI/) CHOI G H.
PA (VRUG/) VAUGHAN T.
PA (HILB/) HILBERT D.
XX
PI Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
XX
DR WPI; 2005-808635/82.
XX
PT New antibodies that immunospecifically binds to B Lymphocyte Stimulator
PT protein, useful for diagnosing, treating, or preventing autoimmune
PT disease, e.g. systemic lupus erythematosus or rheumatoid arthritis, or B
PT cell cancer.
XX
PS Claim 1; SEQ ID NO 1626; 240pp; English.
XX
CC The invention relates to a novel antibody that immunospecifically binds
CC to a B Lymphocyte Stimulator protein. The protein comprises an amino acid
CC sequence that is 85% identical to the VH domain of any one of the single-
CC chain variable fragments (scFvs) of SEQ ID NOs. 1-2128, and/or an amino
CC acid sequence that is at least 85% identical to the VL domain of any one
CC of the scFvs of SEQ ID NOs. 1-2128. The invention further comprises: an
CC isolated nucleic acid molecule encoding the antibody; an isolated cell
CC line that expresses the antibody; a method for detecting the expression
CC of a B Lymphocyte Stimulator protein; a method for diagnosing an
CC autoimmune disease or a B cell cancer; and a method for treating,
CC preventing, or ameliorating an autoimmune disease or a B cell cancer. The
CC antibody is useful for detecting expression of B Lymphocyte Stimulator
CC protein, and in diagnosing, treating, preventing, or ameliorating an
CC autoimmune disease or a B cell cancer. The autoimmune disease is systemic
CC lupus erythematosus or rheumatoid arthritis. It can also be used for
CC diagnosing, treating, and preventing immune disorders (e.g. multiple
CC sclerosis, myasthenia gravis, or Hashimoto's disease), inflammatory
CC disorders (e.g. asthma or allergic disorders) infectious diseases (e.g.
CC AIDS), and proliferative disorders (e.g. leukemia, carcinoma, or
CC lymphoma). This sequence represents a single-chain variable fragment
CC polypeptide that immunospecifically binds to a B Lymphocyte Stimulator
CC protein of the invention. Note: This sequence is not shown in the
CC specification. It has been electronically downloaded from the USPTO
CC website.
XX
SQ Sequence 255 AA;

Query Match 83.5%; Score 71; DB 9; Length 255;
Best Local Similarity 65.0%; Pred. No. 0.00045;
Matches 13; Conservative 1; Mismatches 6; Indels 0; Gaps 0;

Qy 1 TGYYXXXXQSPEKSLEWIG 20
        :||| |||||| ||||
Db 30 SGYYWSWVRQSPEKGLEWIG 49

RESULT 12
ADZ51037
ID ADZ51037 standard; protein; 467 AA.
XX
AC ADZ51037;
XX
DT 30-JUN-2005 (first entry)
XX
DE Amino acid sequence of heavy chain of anti-H4-1BB antibody.
XX
KW antibody therapy; H4-1BB; CD137; IgG4; cytostatic; immunosuppressive;
KW antiinflammatory; antimicrobial; gene therapy;
KW T cell mediated autoimmune disease; cancer; neoplasm; autoimmune disease;
KW inflammatory disease; infectious disease; heavy chain.
XX
OS Synthetic.
XX
FH Key   Location/Qualifiers
FT Peptide   1..19
FT   /note= "leader peptide"
XX
PN WO200503584-A1.

XX
PD   21-APR-2005.
XX
PF   12-OCT-2004; 2004WO-US033587.
XX
PR   10-OCT-2003; 2003US-0510193P.
PR   08-OCT-2004; 2004US-00961567.
XX
PA   (BRIM) BRISTOL-MYERS SQUIBB CO.
XX
PI   Jure-Kunkel M, Hefta LJ, Santoro M, Ganguly S;
XX
DR   WPI; 2005-296269/30.
DR   N-PSDB; AD251035.
XX
PT   New monoclonal antibody that specifically binds to 4-1BB comprises a
PT   light chain variable region and a heavy chain variable region, useful for
PT   treating cancer, autoimmune diseases, inflammatory diseases, or
PT   infectious diseases.
XX
PS   Claim 3; SEQ ID NO 3; 92pp; English.
XX
CC   The specification describes fully human antibodies against human 4-1BB
CC   (CD137) (H4-1BB). These antibodies are especially IgG4 antibodies.
CC   Antibodies for human 4-1BB are useful as immuno-enhancers of an anti-
CC   tumor or anti-viral immune response, or as immunomodulators of T cell
CC   mediated autoimmune disease. They can also be used as diagnostic tools
CC   for the detection of H4-1BB in blood or tissues of patients with cancer,
CC   autoimmune, or other disease. The antibody can also be used for treating
CC   cancer (prostate cancer, melanoma, or epithelial cancer), autoimmune
CC   diseases (multiple sclerosis, rheumatoid arthritis, systemic lupus
CC   erythematosus, or myasthenia gravis), inflammatory diseases, and
CC   infectious diseases. AD251035, AD251036, and AD251037 represent the
CC   coding strand, complementary strand, and encoded protein of a plasmid.
CC   This plasmid encodes the heavy chain of an antibody of the invention.
XX
SQ   Sequence 467 AA;

Qy   Query Match   83.5%; Score 71; DB 9; Length 467;
     Best Local Similarity   65.0%; Pred. No. 0.00087;
     Matches   13; Conservative   1; Mismatches   6; Indels   0; Gaps   0;

Qy   1 TGYYXXXXQSPEKSLEWIG 20
                :||| |||||||||| |||||
Db   49 SGYYWSWIRQSPEKGLEWIG 68

RESULT 13
AD251043
ID   AD251043 standard; protein; 470 AA.
XX
AC   AD251043;
XX
DT   30-JUN-2005 (first entry)
XX
DE   Amino acid sequence of heavy chain of anti-H4-1BB antibody.
XX
KW   antibody therapy; H4-1BB; CD137; IgG4; cytostatic; immunosuppressive;
KW   antiinflammatory; antimicrobial; gene therapy;
KW   T cell mediated autoimmune disease; cancer; neoplasm; autoimmune disease;
KW   inflammatory disease; infectious disease; heavy chain.
XX
OS   Synthetic.
XX
FH   Key   Location/Qualifiers
FT   Peptide   1..19
FT   /note= "leader peptide"
XX
PN   WO2005035584-A1.
XX
PD   21-APR-2005.
XX
PF   12-OCT-2004; 2004WO-US033587.

XX
PR   10-OCT-2003; 2003US-0510193P.
PR   08-OCT-2004; 2004US-00961567.
XX
PA   (BRIM) BRISTOL-MYERS SQUIBB CO.
XX
PI   Jure-Kunkel M, Hefta LJ, Santoro M, Ganguly S;
XX
DR   WPI; 2005-296269/30.
DR   N-PSDB; AD251041.
XX
PT   New monoclonal antibody that specifically binds to 4-1BB comprises a
PT   light chain variable region and a heavy chain variable region, useful for
PT   treating cancer, autoimmune diseases, inflammatory diseases, or
PT   infectious diseases.
XX
PS   Example 1; SEQ ID NO 9; 92pp; English.
XX
CC   The specification describes fully human antibodies against human 4-1BB
CC   (CD137) (H4-1BB). These antibodies are especially IgG4 antibodies.
CC   Antibodies for human 4-1BB are useful as immuno-enhancers of an anti-
CC   tumor or anti-viral immune response, or as immunomodulators of T cell
CC   mediated autoimmune disease. They can also be used as diagnostic tools
CC   for the detection of H4-1BB in blood or tissues of patients with cancer,
CC   autoimmune, or other disease. The antibody can also be used for treating
CC   cancer (prostate cancer, melanoma, or epithelial cancer), autoimmune
CC   diseases (multiple sclerosis, rheumatoid arthritis, systemic lupus
CC   erythematosus, or myasthenia gravis), inflammatory diseases, and
CC   infectious diseases. AD251041, AD251042, and AD251043 represent the
CC   coding strand, complementary strand, and encoded protein of a construct
CC   encoding the heavy chain of an antibody of the invention.
XX
SQ   Sequence 470 AA;

Qy   Query Match   83.5%; Score 71; DB 9; Length 470;
     Best Local Similarity   65.0%; Pred. No. 0.00088;
     Matches   13; Conservative   1; Mismatches   6; Indels   0; Gaps   0;

Qy   1 TGYYXXXXQSPEKSLEWIG 20
                :||| |||||||||| |||||
Db   49 SGYYWSWIRQSPEKGLEWIG 68

RESULT 14
ADD28121
ID   ADD28121 standard; protein; 97 AA.
XX
AC   ADD28121;
XX
DT   15-JAN-2004 (first entry)
XX
DE   Lymphoma related immunoglobulin variable region.
XX
KW   B-cell; malignant; immunoglobulin; immunoglobulin variable region;
KW   Ig variable region; glycosylation site; lymphoma; B cell receptor;
KW   cytostatic; gene therapy; glycosylation inhibitor;
KW   non-Hodgkin's lymphoma.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO2003074059-A2.
XX
PD   12-SEP-2003.
XX
PF   24-FEB-2003; 2003WO-GB000783.
XX
PR   07-MAR-2002; 2002GB-00005395.
XX
PA   (CANC-) CANCER RES TECHNOLOGY LTD.
XX
PI   Zhu D, Stevenson F;
XX

DR   WPI; 2003-902720/82.
XX
PT   Classifying a B-cell as malignant or normal by isolating a sequence
PT   representing an Ig variable region from the B cell, detecting the
PT   presence of a glycosylation site and classifying the cell as malignant or
PT   normal.
XX
PS   Disclosure; Fig 4; 61pp; English.
XX
CC   The present invention describes a method for classifying a B-cell as
CC   malignant or normal comprising: (a) isolating a sequence representing an
CC   immunoglobulin (Ig) variable region from the B cell; (b) detecting the
CC   presence of a glycosylation site; and (c) classifying the cell as
CC   malignant or normal on the basis of the presence or absence of a
CC   glycosylation site. Also described: (1) treating a patient suffering from
CC   or at risk of having lymphoma; (2) screening for substances capable of
CC   inhibiting glycosylation of the Ig variable region of the B cell receptor
CC   ; and (3) screening for substances (S) capable of inhibiting the
CC   interaction between lectins of the type found in the germinal centre and
CC   N-glycans found on the surface of Ig of lymphoma cells. (S) has
CC   cytostatic activity, and can be used in gene therapy, and as a
CC   glycosylation inhibitor. The method is useful in classifying a B-cell as
CC   malignant or normal. The glycosylation inhibitor is useful in preparing a
CC   medicament for treating non-Hodgkin's lymphoma. The present sequence
CC   represents an Ig variable region sequence which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 97 AA;

Query Match   82.4%;   Score 70;   DB 7;   Length 97;
Best Local Similarity   68.4%;   Pred. No. 0.00024;
Matches   13;   Conservative   0;   Mismatches   6;   Indels   0;   Gaps   0;

Qy   2 GYXXXXXQSPBKSLEWIG 20
        ||| |||||| |||||
Db   31 GYYWSWIRQSPBKGLEWIG 49

RESULT 15
ABP58454
ID   ABP58454 standard; protein; 672 AA.
XX
AC   ABP58454;
XX
DT   14-APR-2003   (first entry)
XX
DE   Engineered superantigen for human cancer therapy.
XX
KW   Superantigen; staphylococcal enterotoxin; antibody; cancer; tumour;
KW   cytostatic; vaccine; human; SEA/E-120; mutant; mutein.
XX
OS   Homo sapiens.
OS   Staphylococcus sp.
OS   Synthetic.
OS   Chimeric.
XX
FH   Key   Location/Qualifiers
FT   Region   1..120
FT   /note= "5T4 variable heavy chain"
FT   Misc-difference   41
FT   /note= "wild-type His substituted by Pro"
FT   Misc-difference   44
FT   /note= "wild-type Ser substituted by Gly"
FT   Misc-difference   69
FT   /note= "wild-type Ile substituted by Thr"
FT   Misc-difference   113
FT   /note= "wild-type Val substituted by Gly"
FT   Region   121..222
FT   /note= "C242 constant heavy chain"
FT   Region   226..458
FT   /note= "SEA/E-120"
FT   Misc-difference   245
FT   /note= "wild-type Arg substituted by Gly"
FT   Misc-difference   246
FT   /note= "wild-type Asn substituted by Thr"
FT   Misc-difference   249
FT   /note= "wild-type Ser substituted by Gly"
FT   Misc-difference   252
FT   /note= "wild-type Arg substituted by Lys"
FT   Misc-difference   304
FT   /note= "wild-type Lys substituted by Glu"
FT   Misc-difference   306
FT   /note= "wild-type Lys substituted by Glu"
FT   Misc-difference   308
FT   /note= "wild-type Lys substituted by Ser"
FT   Misc-difference   309
FT   /note= "wild-type Lys substituted by Ser"
FT   Misc-difference   452
FT   /note= "wild-type Asp substituted by Ser"
FT   Region   459..565
FT   /note= "5T4 variable light chain"
FT   Misc-difference   469
FT   /note= "wild-type Phe substituted by Ser"
FT   Misc-difference   504
FT   /note= "wild-type Thr substituted by Lys"
FT   Misc-difference   522
FT   /note= "wild-type Ile substituted by Ser"
FT   Misc-difference   532
FT   /note= "wild-type Phe substituted by Leu"
FT   Misc-difference   536
FT   /note= "wild-type Thr substituted by Ser"
FT   Misc-difference   537
FT   /note= "wild-type Leu substituted by Val"
FT   Misc-difference   542
FT   /note= "wild-type Leu substituted by Ala"
FT   Region   566..672
FT   /note= "C242 constant light chain"
XX
PN   WO200302143-A1.
XX
PD   09-JAN-2003.
XX
PF   19-JUN-2002; 2002WO-SE001188.
XX
PR   28-JUN-2001; 2001SE-00002327.
XX
PA   (ACTI-) ACTIVE BIOTECH AB.
XX
PI   Forsberg G, Erlandsson E, Antonsson P, Walse B;
XX
DR   WPI; 2003-201467/19.
XX
PT   Conjugate for therapy, has bacterial superantigen with a region in T-cell
PT   receptor and four regions to determine binding to class II major
PT   histocompatibility complex, antibody to cancer associated cell surface
PT   structure.
XX
PS   Claim 12; Fig 10; 102pp; English.
XX
CC   The present sequence is a conjugate of a bacterial superantigen and an
CC   antibody moiety, and has been designed to target and destroy cancer
CC   cells. The bacterial superantigen is SEA/E-120 (see also ABP58455), which
CC   was derived from staphylococcal enterotoxin E (SEE) by the incorporation
CC   of the following amino acid substitutions to reduce seroreactivity whilst
CC   maintaining production levels and biological activity: R20G, N21T, S24G,
CC   R27K, K79E, K81E, K83S and D227S. SEA/E-120 was genetically fused to the
CC   Fab region of the tumour reactive antibody 5T4. Substitutions were made
CC   in the 5T4 sequence to obtain higher yields: in the heavy chain, H41P,
CC   S44G, I69T and V113G; and in the light chain, F10S, T45K, I63S, F73L,
CC   T77S, L78V and L83A. An expression vector comprising DNA encoding the
CC   conjugate can be used to transform host cells for recombinant production
CC   of the conjugate. The conjugate is useful for treating cancer, including
CC   cancer of the lung, breast, colon, kidney, pancreas, ovary, stomach,
CC   cervix and prostate (claimed)
XX
SQ   Sequence 672 AA;

Query Match   80.0%; Score 68; DB 6; Length 672;
Best Local Similarity   65.0%; Pred. No. 0.0044;
Matches   13; Conservative   0; Mismatches   7; Indels   0; Gaps   0;

Qy   1 TGYXXXXXQSPEKSLEWIG 20
           |||| |||| |||||||
Db   30 TGYYMHWVKQSPGKGLEWIG 49

Search completed: October 18, 2006, 19:26:43
Job time : 95.299 secs

```
              Copyright  GenCore version 5.1.9
              Copyright (c) 1993 - 2006  Biocceleration Ltd.

OM protein - protein search, using sw model

Run on:      October 18, 2006, 19:27:25 ; Search time 13.299 Seconds
                                          (without alignments)
                               144.698 Million cell updates/sec

Title:       US-10-620-621-1
Perfect score: 85
Sequence:    1 TGYYXXXXQSPEKSLEWIG 20
Scoring table: BLOSUM62
             Gapop 10.0 , Gapext 0.5

Searched:    283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters:     283416

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
                 Maximum Match 100%
                 Listing first 45 summaries

Database :   PIR_80:*
             1: pir1:*
             2: pir2:*
             3: pir3:*
             4: pir4:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.
```

SUMMARIES

Result No.	Score	% Query Match	Match Length	DB	ID	Description
1	79	92.9	105	2	PH0978	Ig heavy chain V r
2	63	74.1	107	2	S26320	Ig heavy chain V r
3	63	74.1	108	2	PH0977	Ig heavy chain V r
4	63	74.1	120	2	A49982	Ig heavy chain V r
5	62	72.9	129	1	D2HUWA	Ig heavy chain V-I
6	61	71.8	115	2	S57464	Ig heavy chain V-J
7	60	70.6	136	2	A31933	Ig heavy chain V-J
8	59	69.4	91	2	S13689	Ig heavy chain pre
9	59	69.4	97	2	S26898	Ig heavy chain V r
10	59	69.4	97	2	S26806	Ig heavy chain V r
11	59	69.4	97	2	S26805	Ig heavy chain V r
12	59	69.4	97	2	S14474	Ig heavy chain V r
13	59	69.4	98	2	S17604	Ig heavy chain V r
14	59	69.4	106	2	S37454	Ig mu chain - huma
15	59	69.4	110	2	S13688	Ig heavy chain V r
16	59	69.4	111	2	S13687	Ig heavy chain V r
17	59	69.4	112	2	S13686	Ig heavy chain V r
18	59	69.4	112	2	S13685	Ig heavy chain V r
19	59	69.4	114	2	S26319	Ig heavy chain V r
20	59	69.4	122	2	JL0047	Ig heavy chain V r
21	59	69.4	126	2	S47010	Ig heavy chain V4.
22	59	69.4	135	2	PS0057	Ig heavy chain pre
23	59	69.4	140	2	S78052	Ig heavy chain pre
24	59	69.4	140	2	A49045	Ig heavy chain V r
25	58	68.2	86	2	F34964	Ig heavy chain V-I
26	58	68.2	98	2	S26912	Ig heavy chain V r
27	58	68.2	98	2	S26938	Ig heavy chain V r
28	58	68.2	98	2	S26902	Ig heavy chain V r
29	58	68.2	98	2	S12421	Ig heavy chain V r
30	58	68.2	99	2	S26801	Ig heavy chain V r
31	58	68.2	99	2	S26807	Ig heavy chain V r
32	58	68.2	104	2	S69899	Ig heavy chain V r
33	58	68.2	109	2	PH1668	Ig heavy chain V r
34	58	68.2	110	2	PH1669	Ig heavy chain V r
35	58	68.2	116	2	S37456	Ig mu chain - huma
36	58	68.2	117	1	HVHU35	Ig heavy chain pre
37	58	68.2	117	2	S18551	Ig heavy chain V r
38	58	68.2	118	2	S36265	Ig heavy chain V r
39	58	68.2	123	2	S30530	Ig heavy chain V r
40	58	68.2	126	2	I44151	Ig heavy chain V r
41	58	68.2	129	2	S46393	Ig heavy chain V r
42	58	68.2	135	2	S49530	anti-Sm antibody V
43	58	68.2	137	2	A34903	Ig heavy chain pre
44	58	68.2	140	2	A24770	hypothetical hybri
45	57	67.1	117	1	G2MSU1	Ig heavy chain V r

ALIGNMENTS

```
RESULT 1
PH0978
Ig heavy chain V region (clone 17s.166) - mouse (fragment)
C;Species: Mus musculus (house mouse)
C;Date: 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 21-Jan-2000
C;Accession: PH0978
R;Tillman, D.M.; Jou, N.T.; Hill, R.J.; Marion, T.N.
J. Exp. Med. 176, 761-779, 1992
A;Title: Both IgM and IgG anti-DNA antibodies are the products of clonally selective B
A;Reference number: PH0971; MUID:92381444; PMID:1512540
A;Accession: PH0978
A;Status: nucleic acid sequence not shown
A;Molecule type: mRNA
A;Residues: 1-105 <TIL>
A;Cross-references: UNIPARC:UPI0000176ACA
A;Experimental source: B cell, strain [NZB x NZW]F1
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;14-97/Domain: immunoglobulin homology <IMM>

Query Match             92.9%;  Score 79;  DB 2;  Length 105;
Best Local Similarity   75.0%;  Pred. No. 7.7e-07;
Matches   15;  Conservative   0;  Mismatches   5;  Indels   0;  Gaps   0;

Qy       1 TGYYXXXXQSPEKSLEWIG 20
             |||    |||||||||||
Db      29 TGYYMHWVKQSPEKSLEWIG 48


RESULT 2
S26320
Ig heavy chain V region - mouse
C;Species: Mus musculus (house mouse)
C;Date: 13-Jan-1995 #sequence_revision 13-Jan-1995 #text_change 21-Jan-2000
C;Accession: S26320
R;Stark, S.E.; Caton, A.J.
J. Exp. Med. 174, 613-624, 1991
A;Title: Antibodies that are specific for a single amino acid interchange in a protein
A;Reference number: S26309; MUID:91341421; PMID:1908510
A;Accession: S26320
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-107 <STA>
A;Cross-references: UNIPARC:UPI0000176ADF; EMBL:X59206
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;3-86/Domain: immunoglobulin homology <IMM>

Query Match             74.1%;  Score 63;  DB 2;  Length 107;
Best Local Similarity   65.0%;  Pred. No. 0.00056;
Matches   13;  Conservative   0;  Mismatches   7;  Indels   0;  Gaps   0;
```

```
Qy   1 TGYYXXXXQSPEKSLEWIG 20
         |||| || |||||||
Db  18 TGYYMHWKQSHVKSLEWIG 37
```

RESULT 3
PH0977
Ig heavy chain V region (clone 10-c1) - mouse (fragment)
C;Species: Mus musculus (house mouse)
C;Date: 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 21-Jan-2000
C;Accession: PH0977
R;Tillman, D.M.; Jou, N.T.; Hill, R.J.; Marion, T.N.
J. Exp. Med. 176, 761-779, 1992
A;Title: Both IgM and IgG anti-DNA antibodies are the products of clonally selective B c
A;Reference number: PH0971; MUID:92381444; PMID:1512540
A;Accession: PH0977
A;Status: nucleic acid sequence not shown
A;Molecule type: mRNA
A;Residues: 1-108 <TIL>
A;Cross-references: UNIPARC:UPI0000176AC9
C;Experimental source: B cell, strain [NZB x NZW]F1
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;15-98/Domain: immunoglobulin homology <IMM>

Query Match   74.1%; Score 63; DB 2; Length 108;
Best Local Similarity 65.0%; Pred. No. 0.00056;
Matches 13; Conservative 1; Mismatches 6; Indels 0; Gaps 0;

```
Qy   1 TGYYXXXXQSPEKSLEWIG 20
         |||| ||||||||
Db  30 TGYYVHWKQSPEKSLESLG 49
```

RESULT 4
A49982
Ig heavy chain V region (BA7.1) - mouse (fragment)
C;Species: Mus musculus (house mouse)
C;Date: 10-Nov-1995 #sequence_revision 10-Nov-1995 #text_change 21-Jan-2000
R;Lin, C.; Kieber-Emmons, T.; Villalobos, A.P.; Foster, M.H.; Wahlgren, C.; Kleyman, T.R
J. Biol. Chem. 269, 2805-2813, 1994
A;Title: Topology of an amiloride-binding protein.
A;Reference number: A49982; MUID:94132051; PMID:8300613
A;Accession: A49982
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-120 <LIN>
A;Cross-references: UNIPARC:UPI0000114AA4; GB:L24802; NID:g452096; PIDN:AAA98740.1; PID:
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;15-98/Domain: immunoglobulin homology <IMM>

Query Match   74.1%; Score 63; DB 2; Length 120;
Best Local Similarity 65.0%; Pred. No. 0.00063;
Matches 13; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

```
Qy   1 TGYYXXXXQSPEKSLEWIG 20
         |||| || |||||||
Db  30 TGYYIHWKQSHVKSLEWIG 49
```

RESULT 5
D2HUWA
Ig heavy chain V-II region (Wah) - human
C;Species: Homo sapiens (man)
C;Date: 05-Apr-1983 #sequence_revision 05-Apr-1983 #text_change 09-Jul-2004
C;Accession: A02099
R;Takahashi, N.; Tetaert, D.; Debuire, B.; Lin, L.C.; Putnam, F.W.
Proc. Natl. Acad. Sci. U.S.A. 79, 2850-2854, 1982
A;Title: Complete amino acid sequence of the delta heavy chain of human immunoglobulin D
A;Reference number: A02099; MUID:82222235; PMID:6806818
A;Accession: A02099

A;Molecule type: protein
A;Residues: 1-129 <TAK>
A;Cross-references: UNIPROT:P01824; UNIPARC:UPI000012CEEF
C;Comment: This chain was isolated from an IgD myeloma protein.
C;Genetics:
A;Gene: GDB:IGHV@
A;Cross-references: GDB:128528; OMIM:147070
A;Map position: 14q32.33-14q32.33
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;15-99/Domain: immunoglobulin homology <IMM>

Query Match   72.9%; Score 62; DB 1; Length 129;
Best Local Similarity 60.0%; Pred. No. 0.001;
Matches 12; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

```
Qy   1 TGYYXXXXQSPEKSLEWIG 20
         |||||
Db  32 TGYYWGWIRQPPGKGLEWIG 51
```

RESULT 6
S57464
Ig heavy chain V-J region - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 10-Oct-1995 #sequence_revision 17-Nov-1995 #text_change 23-Jul-1999
C;Accession: S57464
R;Paterson, G.; Wilson, G.; Kennedy, P.G.E.; Willison, H.J.
submitted to the EMBL Data Library, June 1995
A;Description: Analysis of anti-GM1 ganglioside IgM antibodies cloned from motor neurop
A;Reference number: S57408
A;Accession: S57464
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-115 <PAT>
A;Cross-references: UNIPARC:UPI00001137AD; EMBL:X87897; NID:g871273; PIDN:CAA61148.1; P
C;Genetics:
A;Introns: 100/2
C;Superfamily: immunoglobulin V region; immunoglobulin homology
F;15-99/Domain: immunoglobulin homology <IMM>

Query Match   71.8%; Score 61; DB 2; Length 115;
Best Local Similarity 61.1%; Pred. No. 0.0014;
Matches 11; Conservative 1; Mismatches 6; Indels 0; Gaps 0;

```
Qy   3 YYXXXXQSPEKSLEWIG 20
         ||||| |||||||
Db  34 YYWTWIRQSPERGLEWIG 51
```

RESULT 7
A31933
Ig heavy chain precursor V region (XIg8) - African clawed frog (fragment)
C;Species: Xenopus laevis (African clawed frog)
C;Date: 31-Mar-1990 #sequence_revision 31-Mar-1990 #text_change 09-Jul-2004
C;Accession: A31933
R;Schwager, J.; Mikoryak, C.A.; Steiner, L.A.
Proc. Natl. Acad. Sci. U.S.A. 85, 2245-2249, 1988
A;Title: Amino acid sequence of heavy chain from Xenopus laevis IgM deduced from cDNA s
A;Reference number: A94192; MUID:88176921; PMID:2451244
A;Accession: A31933
A;Molecule type: mRNA
A;Residues: 1-136 <SCH>
A;Cross-references: UNIPROT:P20956; UNIPARC:UPI000012CED7
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;32-114/Domain: immunoglobulin homology <IMM>

Query Match   70.6%; Score 60; DB 2; Length 136;
Best Local Similarity 55.0%; Pred. No. 0.0025;
Matches 11; Conservative 1; Mismatches 8; Indels 0; Gaps 0;

```
Qy   1 TGYYXXXXQSPEKSLEWIG 20
```

Db   47 TSYYVYWIRQPPRKTLEWIG 66

RESULT 8
S13689
Ig heavy chain V region - mouse (fragment)
C;Species: Mus musculus (house mouse)
C;Date: 18-Feb-1994 #sequence_revision 10-Nov-1995 #text_change 09-May-1997
C;Accession: S13689
R;Pennell, C.A.; Mercolino, T.J.; Grdina, T.A.; Arnold, L.W.; Haughton, G.; Clarke, S.H.
Eur. J. Immunol. 19, 1289-1295, 1989
A;Title: Biased immunoglobulin variable region gene expression by Ly-1 B cells due to cl
A;Reference number: S13685; MUID:89338557; PMID:2503389
A;Molecule type: mRNA
A;Residues: 1-91 <PEN>
A;Cross-references: UNIPARC:UPI000176903; EMBL:X53342
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin

Query Match   69.4%;   Score 59;   DB 2;   Length 91;
Best Local Similarity   55.0%;   Pred. No. 0.0024;
Matches   11; Conservative   2; Mismatches   7; Indels   0; Gaps   0;

Qy   1 TGYYXXXXQSPEKSLEWIG 20
              :||| ||||||
Db   10 SGYYWIWIRQSPGKPLEWWG 29

RESULT 9
S26898
Ig heavy chain V region (clone DP-63, V(H)4.2) - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 22-Nov-1993 #sequence_revision 10-Nov-1995 #text_change 23-Jul-1999
C;Accession: S26898; S12420
R;Tomlinson, I.M.; Walter, G.; Marks, J.D.; Llewelyn, M.B.; Winter, G.
J. Mol. Biol. 227, 776-798, 1992
A;Title: The repertoire of human germline V(H) sequences reveals about fifty groups of V
A;Reference number: S26885; MUID:93021117; PMID:1404388
A;Accession: S26898
A;Molecule type: DNA
A;Residues: 1-97 <TOM>
A;Cross-references: UNIPARC:UPI0000116417; EMBL:Z12363; NID:g32944; PIDN:CAA78233.1; PID
A;Experimental source: clone DP-63
R;Sanz, I.; Kelly, P.; Williams, C.; Scholl, S.; Tucker, P.; Capra, J.D.
EMBO J. 8, 3741-3748, 1989
A;Title: The smaller human V(H) gene families display remarkably little polymorphism.
A;Reference number: S09421; MUID:90059975; PMID:2511001
A;Accession: S12420
A;Status: translation not shown
A;Molecule type: DNA
A;Residues: 1-97 <SAN>
A;Cross-references: UNIPARC:UPI0000116417; EMBL:X56364
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;15-97/Domain: immunoglobulin homology <IMM>

Query Match   69.4%;   Score 59;   DB 2;   Length 97;
Best Local Similarity   55.0%;   Pred. No. 0.0026;
Matches   11; Conservative   1; Mismatches   8; Indels   0; Gaps   0;

Qy   1 TGYYXXXXQSPEKSLEWIG 20
              :||| ||||||
Db   30 SGYYWSWIRQPPGKGLEWIG 49

RESULT 10
S26806
Ig heavy chain V region - human
C;Species: Homo sapiens (man)
C;Date: 13-Jan-1995 #sequence_revision 13-Jan-1995 #text_change 20-Jun-2000
C;Accession: S26806
R;Weng, N.; Snyder, J.G.; Yu-Lee, L.; Marcus, D.M.
Eur. J. Immunol. 22, 1075-1082, 1992
A;Title: Polymorphism of human immunoglobulin V(H)4 germ-line genes.
A;Reference number: S26800; MUID:92201299; PMID:1348029
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-97 <WEN>
A;Cross-references: UNIPARC:UPI0000116488; EMBL:Z14242; NID:g37716; PIDN:CAA78611.1; PI
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;15-97/Domain: immunoglobulin homology <IMM>

Query Match   69.4%;   Score 59;   DB 2;   Length 97;
Best Local Similarity   55.0%;   Pred. No. 0.0026;
Matches   11; Conservative   1; Mismatches   8; Indels   0; Gaps   0;

Qy   1 TGYYXXXXQSPEKSLEWIG 20
              :||| ||||||
Db   30 SGYYWSWIRQPPGKGLEWIG 49

RESULT 11
S26805
Ig heavy chain V region - human
C;Species: Homo sapiens (man)
C;Date: 13-Jan-1995 #sequence_revision 13-Jan-1995 #text_change 20-Jun-2000
C;Accession: S26805
R;Weng, N.; Snyder, J.G.; Yu-Lee, L.; Marcus, D.M.
Eur. J. Immunol. 22, 1075-1082, 1992
A;Title: Polymorphism of human immunoglobulin V(H)4 germ-line genes.
A;Reference number: S26800; MUID:92201299; PMID:1348029
A;Accession: S26805
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-97 <WEN>
A;Cross-references: UNIPARC:UPI0000116487; EMBL:Z14241; NID:g37714; PIDN:CAA78610.1; PI
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;15-97/Domain: immunoglobulin homology <IMM>

Query Match   69.4%;   Score 59;   DB 2;   Length 97;
Best Local Similarity   55.0%;   Pred. No. 0.0026;
Matches   11; Conservative   1; Mismatches   8; Indels   0; Gaps   0;

Qy   1 TGYYXXXXQSPEKSLEWIG 20
              :||| ||||||
Db   30 SGYYWSWIRQPPGKGLEWIG 49

RESULT 12
S14474
Ig heavy chain V region - human
C;Species: Homo sapiens (man)
C;Date: 20-Feb-1995 #sequence_revision 20-Feb-1995 #text_change 20-Jun-2000
C;Accession: S14474
R;van Es, J.H.; Gmelig Meyling, F.H.J.; van de Akker, W.R.M.; Aanstoot, H.; Derksen, R.I
submitted to the EMBL Data Library, November 1990
A;Reference number: S14474
A;Accession: S14474
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-97 <ESJ>
A;Cross-references: UNIPARC:UPI0000115EC0; EMBL:X56591; NID:g37235; PIDN:CAA39929.1; PI
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;15-97/Domain: immunoglobulin homology <IMM>

Query Match   69.4%;   Score 59;   DB 2;   Length 97;
Best Local Similarity   55.0%;   Pred. No. 0.0026;
Matches   11; Conservative   1; Mismatches   8; Indels   0; Gaps   0;

A;Cross-references: UNIPARC:UPI0000176904; EMBL:X53341
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;10-93/Domain: immunoglobulin homology <IMM>

Query Match   69.4%; Score 59; DB 2; Length 110;
Best Local Similarity   55.0%; Pred. No. 0.0029;
Matches   11; Conservative   2; Mismatches   7; Indels   0; Gaps   0;

Qy   1 TGYYXXXXQSPEKSLEWIG 20
            :|||| ||| ||||||:|
Db   26 SGYYWIWIRQSPGKPLEWMG 45

Search completed: October 18, 2006, 19:46:48
Job time : 13.299 secs

RESULT 13
S17604
Ig heavy chain V region - mouse
C;Species: Mus musculus (house mouse)
C;Date: 22-Nov-1993 #sequence_revision 10-Nov-1995 #text_change 21-Jan-2000
C;Accession: S17604
R;Clackson, T.; Hoogenboom, H.R.; Griffiths, A.D.; Winter, G.
Nature 352, 624-628, 1991
A;Title: Making antibody fragments using phage display libraries.
A;Reference number: S17230; MUID:91326098; PMID:1907718
A;Accession: S17604
A;Status: preliminary
A;Molecule type: nucleic acid
A;Residues: 1-98 <CLA>
A;Cross-references: UNIPARC:UPI0000176D59
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;8-91/Domain: immunoglobulin homology <IMM>

Query Match   69.4%; Score 59; DB 2; Length 98;
Best Local Similarity   60.0%; Pred. No. 0.0026;
Matches   12; Conservative   1; Mismatches   7; Indels   0; Gaps   0;

Qy   1 TGYYXXXXQSPEKSLEWIG 20
            :|||| ||||||||
Db   23 TGYFMNWVKQSHGKSLEWIG 42

RESULT 14
S37454
Ig mu chain - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 06-Jan-1995 #sequence_revision 06-Jan-1995 #text_change 23-Jul-1999
C;Accession: S37454
R;McIntosh, R.S.; Tandon, N.; Weetman, A.P.
submitted to the EMBL Data Library, September 1993
A;Description: Cloning and analysis of human IgM anti-Thyroglobulin autoantibodies from
A;Accession: S37454
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-106 <MCI>
A;Cross-references: UNIPARC:UPI00001161BE; EMBL:X75022; NID:g404311; PIDN:CAA52930.1; PI
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: immunoglobulin

Query Match   69.4%; Score 59; DB 2; Length 106;
Best Local Similarity   55.0%; Pred. No. 0.0028;
Matches   11; Conservative   1; Mismatches   8; Indels   0; Gaps   0;

Qy   1 TGYYXXXXQSPEKSLEWIG 20
            :|||| ||| ||||||
Db   8 SGYYWSWIRQPPGKGLEWIG 27

RESULT 15
S13688
Ig heavy chain V region - mouse (fragment)
C;Species: Mus musculus (house mouse)
C;Date: 18-Feb-1994 #sequence_revision 10-Nov-1995 #text_change 30-May-1997
C;Accession: S13688
R;Pennell, C.A.; Mercolino, T.J.; Grdina, T.A.; Arnold, L.W.; Haughton, G.; Clarke, S.H.
Eur. J. Immunol. 19, 1289-1295, 1989
A;Title: Biased immunoglobulin variable region gene expression by Ly-1 B cells due to cl
A;Reference number: S13685; MUID:89338557; PMID:2503389
A;Accession: S13688
A;Molecule type: mRNA
A;Residues: 1-110 <PEN>

Qy   1 TGYYXXXXQSPEKSLEWIG 20
            :|||| ||| ||||||
Db   30 SGYYWSWIRQPPGKGLEWIG 49

Protein Sequence Searches - February 2005

All of the sequence databases on ABSS have recently been updated.

- Please note that the curators of the UniProt database have purged some temporary accession numbers from the most recent version of UniProt. These sequences have been assigned new permanent accession numbers. The new UniProt record may not contain the previous temporary accession number.

- If you encounter an accession number from an older search run against UniProt (results file extension **.rup**) that can no longer be found in the database, the permanent record with the new accession number can be found by searching the old accession number in the UniProt Protein Archive database (UniPARC) at:

  http://www.pir.uniprot.org/database/archive.shtml

If you have any questions regarding this information or your results, please contact any STIC searcher.

When submitting sequence search results for scanning into IFW, please include a copy of this attachment to assist any future Examiners or members of the public who may encounter UniProt temporary accession numbers.

OM protein - protein search, using sw model

Copyright (c) 1993 - 2006 Bioacceleration Ltd.
GenCore version 5.1.9

Run on: October 18, 2006, 19:11:38 ; Search time 110.309 Seconds
(without alignments)
167.713 Million cell updates/sec

Title: US-10-620-621-1
Perfect score: 85
Sequence: 1 TGYYXXXXQSPEKSLEWIG 20

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 2849598 seqs, 925015592 residues

Total number of hits satisfying chosen parameters: 2849598

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : UniProt_7.2:*
1: uniprot_sprot:*
2: uniprot_trembl:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Query Length	DB	ID	Description
1	65	76.5	134	2	Q65ZR6_MOUSE	Q65zr6 mus musculu
2	63	74.1	118	2	Q5R3X0_MOUSE	Q5r3x0 mus musculu
3	63	74.1	150	2	Q95973_HUMAN	Q95973 homo sapien
4	63	74.1	470	2	Q7TMK1_MOUSE	Q7tmk1 mus musculu
5	62	72.9	129	1	HV2F_HUMAN	P01824 homo sapien
6	60	70.6	100	2	Q6BFZ2_RABIT	Q6bfz2 oryctolagus
7	60	70.6	136	1	HV01_XENLA	P20956 xenopus lae
8	59	69.4	119	2	Q9GYZ2_MOUSE	Q9gyz2 mus musculu
9	59	69.4	595	2	Q8WUX4_HUMAN	Q8wux4 homo sapien
10	59	69.4	597	2	Q6GMX5_HUMAN	Q6gmx5 homo sapien
11	59	69.4	597	2	Q9BQB8_HUMAN	Q9bqb8 homo sapien
12	59	69.4	597	2	Q9BU10_HUMAN	Q9bu10 homo sapien
13	59	69.4	625	2	Q96AA6_HUMAN	Q96aa6 homo sapien
14	58	68.2	116	2	Q7Z3Y6_HUMAN	Q7z3y6 homo sapien
15	58	68.2	117	1	HV1G_HUMAN	P23083 homo sapien
16	58	68.2	119	2	Q9UL94_HUMAN	Q9ul94 homo sapien
17	58	68.2	125	2	Q9UL95_HUMAN	Q9ul95 homo sapien
18	57	67.1	117	1	HV41_MOUSE	P01811 mus musculu
19	57	67.1	130	2	Q8IZD7_HUMAN	Q8izd7 homo sapien
20	57	67.1	483	2	Q4VAB6_MOUSE	Q4vab6 mus musculu
21	56	65.9	98	2	Q6BG20_RABIT	Q6bg20 oryctolagus
22	56	65.9	102	2	Q6BGS8_RABIT	Q6bgs8 oryctolagus
23	56	65.9	103	2	Q6B713_RABIT	Q6b713 oryctolagus
24	56	65.9	117	1	HV12_MOUSE	P01756 mus musculu
25	56	65.9	117	1	HV13_MOUSE	P01757 mus musculu
26	56	65.9	117	1	HV17_MOUSE	P01786 mus musculu
27	56	65.9	117	2	Q9QXE9_MOUSE	Q9qxe9 mus musculu
28	56	65.9	117	2	Q9QXF0_MOUSE	Q9qxf0 mus musculu
29	56	65.9	118	1	HV51_MOUSE	P06330 mus musculu
30	56	65.9	146	1	HV2I_HUMAN	P06331 homo sapien
31	56	65.9	488	2	Q91WR1_MOUSE	Q91wr1 mus musculu
32	54	63.5	101	2	Q6B6W2_RABIT	Q6b6w2 oryctolagus
33	54	63.5	102	2	Q6B6U5_RABIT	Q6b6u5 oryctolagus
34	54	63.5	102	2	Q6B6U6_RABIT	Q6b6u6 oryctolagus
35	54	63.5	113	1	HV29_MOUSE	P01798 mus musculu
36	54	63.5	120	2	Q920E8_MOUSE	Q920e8 mus musculu
37	53	62.4	98	1	HV57_MOUSE	P18528 mus musculu
38	53	62.4	99	2	Q6B6U4_RABIT	Q6b6u4 oryctolagus
39	53	62.4	111	1	HV35_MOUSE	P01804 mus musculu
40	53	62.4	113	1	HV27_MOUSE	P01796 mus musculu
41	53	62.4	113	1	HV28_MOUSE	P01797 mus musculu
42	53	62.4	113	1	HV30_MOUSE	P01799 mus musculu
43	53	62.4	113	1	HV31_MOUSE	P01800 mus musculu
44	53	62.4	113	1	HV34_MOUSE	P01803 mus musculu
45	53	62.4	115	1	HV32_MOUSE	P01801 mus musculu

ALIGNMENTS

RESULT 1
Q65ZR6_MOUSE
ID   Q65ZR6_MOUSE   PRELIMINARY;   PRT;   134 AA.
AC   Q65ZR6;
DT   11-OCT-2004, integrated into UniProtKB/TrEMBL.
DT   11-OCT-2004, sequence version 1.
DT   07-FEB-2006, entry version 10.
DE   Ab 126.33 heavy chain variable and joining regions (Fragment).
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE.
RX   MEDLINE=91237115; PubMed=1709665;
RA   Rueff-Juy D., Marche P.N., Drapier A.-M., Cazenave P.-A.;
RT   "Junctional diversity of H and L chains allows the coexpression of two
RT   mutually exclusive idiotopes (Id1104 and Id1558).";
RL   J. Immunol. 146:4024-4030(1991).

DR   EMBL; M74139; AAA37776.1; -; mRNA.
DR   SMR; Q65ZR6; 18-134.
DR   Ensembl; ENSMUSG00000057641; Mus musculus.
DR   InterPro; IPR003599; Ig.
DR   InterPro; IPR007110; Ig-like.
DR   InterPro; IPR003596; Ig_v.
DR   InterPro; IPR013106; V-set.
DR   SMART; SM00409; IG; 1.
DR   SMART; SM00406; IGv; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
KW   Immunoglobulin domain.
FT   NON_TER   1   1
SQ   SEQUENCE   134 AA; 14908 MW; 1852D86D26FC7567 CRC64;

Query Match   76.5%; Score 65; DB 2; Length 134;
Best Local Similarity   65.0%; Pred. No. 0.002;
Matches   13; Conservative   0; Mismatches   7; Indels   0; Gaps   0;

Qy   1 TGYYXXXXQSPEKSLEWIG 20
                ||| ||||||||||
Db   47 TDYYMKWVKQSPGKSLEWIG 66

RESULT 2
Q5R3X0_MOUSE
ID   Q5R3X0_MOUSE   PRELIMINARY;   PRT;   118 AA.
AC   Q5R3X0;
DT   21-DEC-2004, integrated into UniProtKB/TrEMBL.
DT   21-DEC-2004, sequence version 1.
DT   07-FEB-2006, entry version 8.

RA   Strausberg R.;
RL   Submitted (AUG-2003) to the EMBL/GenBank/DDBJ databases.
CC   ---
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   ---
DR   EMBL; BC055910; AAH55910.1; -; mRNA.
DR   HSSP; P01865; 1K8B.
DR   MGI; MGI:2144790; AI324046.
DR   InterPro; IPR003599; Ig.
DR   InterPro; IPR007110; Ig-like.
DR   InterPro; IPR003597; Ig_c1.
DR   InterPro; IPR003006; Ig_MHC.
DR   InterPro; IPR003596; Ig_v.
DR   InterPro; IPR013106; V-set.
DR   Pfam; PF07654; C1-set; 3.
DR   SMART; SM00409; IG; 1.
DR   SMART; SM00407; IGc1; 2.
DR   SMART; SM00406; IGv; 1.
DR   PROSITE; PS50835; IG_LIKE; 4.
DR   PROSITE; PS00290; IG_MHC; UNKNOWN_1.
KW   Hypothetical protein.
SQ   SEQUENCE   470 AA; 51728 MW; 6D90E4DF896BB090 CRC64;

Query Match   74.1%; Score 63; DB 2; Length 470;
Best Local Similarity   65.0%; Pred. No. 0.018;
Matches   13; Conservative   0; Mismatches   7; Indels   0; Gaps   0;

Qy   1 TGYYXXXXQSPEKSLEWIG 20
              ||||| |||||||
Db   49 TGYYMHWVKQSHGKSLEWIG 68

RESULT 5
HV2F_HUMAN
ID   HV2F_HUMAN   STANDARD;   PRT;   129 AA.
AC   P01824;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   21-JUL-1986, sequence version 1.
DT   07-MAR-2006, entry version 36.
DE   Ig heavy chain V-II region WAH.
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   PROTEIN SEQUENCE.
RX   MEDLINE=82222235; PubMed=6806818;
RA   Takahashi N., Tetaert D., Debuire B., Lin L.-C., Putnam F.W.;
RT   "Complete amino acid sequence of the delta heavy chain of human
RT   immunoglobulin D.";
RL   Proc. Natl. Acad. Sci. U.S.A. 79:2850-2854(1982).
CC   -!- MISCELLANEOUS: This chain was isolated from an IgD myeloma
CC   protein.
CC   -!- SIMILARITY: Contains 1 Ig-like (immunoglobulin-like) domain.
CC   ---
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   ---
DR   PIR; A02099; D2HUWA.
DR   PDB; 1ZVO; X-ray; C/D=-.
DR   SMR; P01824; 2-129.
DR   GlycoSuiteDB; P01824; -.
DR   GO; GO:0005576; C:extracellular region; NAS.
DR   GO; GO:0003823; F:antigen binding; NAS.
DR   GO; GO:0006955; P:immune response; NAS.
DR   InterPro; IPR003599; Ig.
DR   InterPro; IPR007110; Ig-like.
DR   InterPro; IPR003596; Ig_v.
DR   InterPro; IPR013106; V-set.
DR   Pfam; PF07686; V-set; 1.
DR   SMART; SM00409; IG; 1.
DR   SMART; SM00406; IGv; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
KW   3D-structure; Direct protein sequencing; Immunoglobulin domain;
KW   Immunoglobulin V region.
FT   CHAIN   1   >129   Ig heavy chain V-II region WAH.
FT   /FTId=PRO_0000059912.
FT   DOMAIN   1   113   Ig-like.
FT   NON_TER   129   129
SQ   SEQUENCE   129 AA; 14117 MW; D5D53D47ABE51319 CRC64;

Query Match   72.9%; Score 62; DB 1; Length 129;
Best Local Similarity   60.0%; Pred. No. 0.0067;
Matches   12; Conservative   0; Mismatches   8; Indels   0; Gaps   0;

Qy   1 TGYYXXXXQSPEKSLEWIG 20
              ||||| || |||||
Db   32 TGYYWGWIRQPPGKGLEWIG 51

RESULT 6
Q6B622_RABIT
ID   Q6B622_RABIT   PRELIMINARY;   PRT;   100 AA.
AC   Q6B622;
DT   13-SEP-2004, integrated into UniProtKB/TrEMBL.
DT   13-SEP-2004, sequence version 1.
DT   07-FEB-2006, entry version 10.
DE   Immunoglobulin heavy chain variable region (Fragment).
OS   Oryctolagus cuniculus (Rabbit).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Lagomorpha; Leporidae;
OC   Oryctolagus.
OX   NCBI_TaxID=9986;
RN   [1]
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=New Zealand;
RX   PubMed=15623575; DOI=10.1084/jem.20041849;
RA   Rhee K.J., Jasper P.J., Sethupathi P., Shanmugam M., Lanning D.,
RA   Knight K.L.;
RT   "Positive selection of the peripheral B cell repertoire in gut-
RT   associated lymphoid tissues.";
RL   J. Exp. Med. 201:55-62(2005).
RN   [2]
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=New Zealand;
RA   Rhee K.-J., Jasper P.J., Sethupathi P., Knight K.L.;
RL   Submitted (JUL-2004) to the EMBL/GenBank/DDBJ databases.
CC   ---
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   ---
DR   EMBL; AY676781; AAT91215.1; -; mRNA.
DR   InterPro; IPR007110; Ig-like.
DR   InterPro; IPR003596; Ig_v.
DR   InterPro; IPR013106; V-set.
DR   SMART; SM00406; IGv; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
FT   NON_TER   1   1
FT   NON_TER   100   100
SQ   SEQUENCE   100 AA; 10513 MW; 5D3FDC87553C9680 CRC64;

Query Match   70.6%; Score 60; DB 2; Length 100;
Best Local Similarity   55.0%; Pred. No. 0.012;
Matches   11; Conservative   2; Mismatches   7; Indels   0; Gaps   0;

Qy   1 TGYYXXXXQSPEKSLEWIG 20
              ||||| |: | |||||
Db   33 SGYYMCWVRQAPGKGLEWIG 52

RESULT 7
HV01_XENLA
ID   HV01_XENLA   STANDARD;   PRT;   136 AA.
AC   P20556;

```
RT   "Nucleotide sequences of eight human natural autoantibody VH regions
RT   reveals apparent restricted use of VH families.";
RL   J. Immunol. 142:4054-4061(1989).
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; BC019235; AAH19235.2; -; mRNA.
DR   PIR; G34964; G34964.
DR   HSSP; P01861; 1ADQ.
DR   SMR; Q8WUX4; 27-256.
DR   Ensembl; ENSG00000130076; Homo sapiens.
DR   InterPro; IPR003599; Ig.
DR   InterPro; IPR007110; Ig-like.
DR   InterPro; IPR003597; Ig_c1.
DR   InterPro; IPR003006; Ig_MHC.
DR   InterPro; IPR003596; Ig_v.
DR   InterPro; IPR013106; V-set.
DR   Pfam; PF07654; C1-set; 4.
DR   SMART; SM00409; IG; 1.
DR   SMART; SM00407; IGc1; 3.
DR   SMART; SM00406; IGv; 1.
DR   PROSITE; PS50835; IG_LIKE; 5.
DR   PROSITE; PS00290; IG_MHC; UNKNOWN_3.
SQ   SEQUENCE 595 AA; 65291 MW; 0D4B50776545714E CRC64;

Query Match             69.4%;  Score 59;  DB 2;  Length 595;
Best Local Similarity   55.0%;  Pred. No. 0.13;
Matches   11;  Conservative    1;  Mismatches    8;  Indels    0;  Gaps    0;

Qy   1 TGYYXXXXQSPEKSLEWIG 20
          ::||||||:|||||
Db  56 SGYYWSWIRQPPGKGLEWIG 75

RESULT 10
Q6GMX5_HUMAN
ID   Q6GMX5_HUMAN     PRELIMINARY;     PRT;   597 AA.
AC   Q6GMX5;
DT   19-JUL-2004, integrated into UniProtKB/TrEMBL.
DT   19-JUL-2004, sequence version 1.
DT   07-FEB-2006, entry version 17.
DE   IGHM protein.
GN   Name=IGHM;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Lymph;
RX   MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA   Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA   Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA   Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA   Hopkins R.F., Jordan M., Moore T., Max S.I., Wang J., Hsieh F.,
RA   Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA   Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA   Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA   Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA   Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA   Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA   Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA   Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S., Sanchez A.,
RA   Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA   Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA   Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA   Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA   Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.,
RT   "Generation and initial analysis of more than 15,000 full-length human
RT   and mouse cDNA sequences.";
```

```
RL   Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN   [2]
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Lymph;
RG   NIH MGC Project;
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; BC073767; AAH73767.1; -; mRNA.
DR   SMR; Q6GMX5; 20-249.
DR   Ensembl; ENSG00000130076; Homo sapiens.
DR   InterPro; IPR003599; Ig.
DR   InterPro; IPR007110; Ig-like.
DR   InterPro; IPR003597; Ig_c1.
DR   InterPro; IPR003006; Ig_MHC.
DR   InterPro; IPR003596; Ig_v.
DR   InterPro; IPR013106; V-set.
DR   Pfam; PF07654; C1-set; 4.
DR   SMART; SM00409; IG; 1.
DR   SMART; SM00407; IGc1; 3.
DR   SMART; SM00406; IGv; 1.
DR   PROSITE; PS50835; IG_LIKE; 5.
DR   PROSITE; PS00290; IG_MHC; UNKNOWN_3.
KW   Hypothetical protein.
SQ   SEQUENCE 597 AA; 65305 MW; 2A1E75F6AED85230 CRC64;

Query Match             69.4%;  Score 59;  DB 2;  Length 597;
Best Local Similarity   55.0%;  Pred. No. 0.13;
Matches   11;  Conservative    1;  Mismatches    8;  Indels    0;  Gaps    0;

Qy   1 TGYYXXXXQSPEKSLEWIG 20
          ::||||||:|||||
Db  49 SGYYWSWIRQPPGKGLEWIG 68

RESULT 11
Q9BQB8_HUMAN
ID   Q9BQB8_HUMAN     PRELIMINARY;     PRT;   597 AA.
AC   Q9BQB8;
DT   01-JUN-2001, integrated into UniProtKB/TrEMBL.
DT   01-JUN-2001, sequence version 1.
DT   07-FEB-2006, entry version 27.
DE   IGHM protein.
GN   Name=IGHM;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Muscle;
RX   MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA   Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA   Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA   Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA   Hopkins R.F., Jordan M., Moore T., Max S.I., Wang J., Hsieh F.,
RA   Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA   Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA   Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA   Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA   Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA   Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA   Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA   Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S., Sanchez A.,
RA   Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA   Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA   Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA   Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA   Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.,
RT   "Generation and initial analysis of more than 15,000 full-length human
RT   and mouse cDNA sequences.";
```

RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Lymph;
RG NIH MGC Project;
RL Submitted (NOV-2001) to the EMBL/GenBank/DDBJ databases.
RN [3]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=91252286; PubMed=1904154;
RA Neale G.A., Kitchingman G.R.;
RT "mRNA transcripts initiating within the human immunoglobulin mu heavy
RT chain enhancer region contain a non-translatable exon and are
RT extremely heterogeneous at the 5' end.";
RL Nucleic Acids Res. 19:2427-2433(1991).
CC Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution-NoDerivs License
CC -----
DR EMBL; BC017356; AAH17356.2; -; mRNA.
DR PIR; S15590; S15590.
DR HSSP; P01861; 1ADQ.
DR SMR; Q96AA6; 27-256.
DR Ensembl; ENSG00000130076; Homo sapiens.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig_c1.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR InterPro; IPR013106; v-set.
DR Pfam; PF07654; C1-set; 4.
DR SMART; SM00409; IG; 1.
DR SMART; SM00407; IGc1; 3.
DR SMART; SM00406; IGv; 1.
DR PROSITE; PS50835; IG_LIKE; 5.
DR PROSITE; PS00290; IG_MHC; UNKNOWN 3.
SQ SEQUENCE 625 AA; 68611 MW; F62FAB3ADE7ECBFE CRC64;

Query Match 69.4%; Score 59; DB 2; Length 625;
Best Local Similarity 55.0%; Pred. No. 0.14;
Matches 11; Conservative 1; Mismatches 8; Indels 0; Gaps 0;

Qy 1 TGYYXXXXQSPEKSLEWIG 20
:||| ||||| |||||
Db 56 SGYYWSWIRQPPGKGLEWIG 75

RESULT 14
Q7Z3Y6_HUMAN
ID Q7Z3Y6_HUMAN PRELIMINARY; PRT; 116 AA.
AC Q7Z3Y6;
DT 01-OCT-2003, integrated into UniProtKB/TrEMBL.
DT 01-OCT-2003, sequence version 1.
DT 07-FEB-2006, entry version 14.
DE Rearranged VH4-34 V gene segment (Fragment).
GN Name=VH4-34;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Hodgkin lymphoma;
RA Tinguely M., Rosenquist R., Sundstroem C., Amini R.M., Kuppers R.,
RA Hansmann M.L., Brauninger A.;
RL Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
CC -----
CC Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution-NoDerivs License
CC -----
DR EMBL; AJ564425; CAD92032.1; -; Genomic_DNA.

DR HSSP; P18532; 1KCV.
DR SMR; Q7Z3Y6; 1-97.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR InterPro; IPR013106; V-set.
DR SMART; SM00409; IG; 1.
DR SMART; SM00406; IGv; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
KW Immunoglobulin domain.
FT NON_TER 1 1
FT NON_TER 116 116
SQ SEQUENCE 116 AA; 12903 MW; CE3D8A846616C908 CRC64;

Query Match 68.2%; Score 58; DB 2; Length 116;
Best Local Similarity 55.0%; Pred. No. 0.032;
Matches 11; Conservative 1; Mismatches 8; Indels 0; Gaps 0;

Qy 1 TGYYXXXXQSPEKSLEWIG 20
:||| ||||| |||||
Db 30 SGYYNWIRQPPGKGLEWIG 49

RESULT 15
HV1G_HUMAN
ID HV1G_HUMAN STANDARD; PRT; 117 AA.
AC P23083;
DT 01-NOV-1991, integrated into UniProtKB/Swiss-Prot.
DT 01-NOV-1991, sequence version 1.
DT 07-MAR-2006, entry version 36.
DE Ig heavy chain V-I region V35 precursor.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX MEDLINE=88296408; PubMed=2841108;
RA Matsuda F., Lee K.H., Nakai S., Sato T., Kodaira M., Zong S.Q.,
RA Ohno H., Fukuhara S., Honjo T.;
RT "Dispersed localization of D segments in the human immunoglobulin
RT heavy-chain locus.";
RL EMBO J. 7:1047-1051(1988).
RN [2]
RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 20-116.
RX MEDLINE=93209281; PubMed=7681398;
RA Mariette X., Tsapis A., Brouet J.C.;
RT "Nucleotidic sequence analysis of the variable domains of four human
RT monoclonal IgM with an antibody activity to myelin-associated
RT glycoprotein.";
RL Eur. J. Immunol. 23:846-851(1993).
-!- SIMILARITY: Contains 1 Ig-like (immunoglobulin-like) domain.
CC Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution-NoDerivs License
CC -----
DR EMBL; X07448; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR PIR; S00476; HVHU35.
DR HSSP; P01751; 1NQB.
DR SMR; P23083; 20-117.
DR Ensembl; ENSG00000130076; Homo sapiens.
DR LinkHub; P23083; -.
DR GO; GO:0005576; C:extracellular region; NAS.
DR GO; GO:0003823; F:antigen binding; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR InterPro; IPR013106; V-set.
DR Pfam; PF07686; V-set; 1.
DR SMART; SM00406; IGv; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
KW Immunoglobulin domain; Immunoglobulin V region; Signal.

```
                   Copyright   GenCore version 5.1.9
                               Copyright (c) 1993 - 2006  Bioacceleration Ltd.

OM protein - protein search, using sw model

Run on:        October 18, 2006, 19:45:04 ; Search time 24.1237 Seconds
                                             (without alignments)
                                             72.568 Million cell updates/sec

Title:         US-10-620-621-1
Perfect score: 85
Sequence:      1 TGYYXXXXQSPEKSLEWIG 20

Scoring table: BLOSUM62
               Gapop 10.0 , Gapext 0.5

Searched:      650591 seqs, 87530628 residues

Total number of hits satisfying chosen parameters:    650591

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
                 Maximum Match 100%
                 Listing first 45 summaries

Database :     Issued Patents_AA:*
  1: /EMC_Celerra_SIDS3/ptodata/2/iaa/5_COMB.pep:*
  2: /EMC_Celerra_SIDS3/ptodata/2/iaa/6_COMB.pep:*
  3: /EMC_Celerra_SIDS3/ptodata/2/iaa/7_COMB.pep:*
  4: /EMC_Celerra_SIDS3/ptodata/2/iaa/H_COMB.pep:*
  5: /EMC_Celerra_SIDS3/ptodata/2/iaa/PCTUS_COMB.pep:*
  6: /EMC_Celerra_SIDS3/ptodata/2/iaa/RE_COMB.pep:*
  7: /EMC_Celerra_SIDS3/ptodata/2/iaa/backfiles1.pep:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.
```

SUMMARIES

Result No.	Score	% Match	Match Length	Query Length	DB	ID	Description
1	80	94.1	20	20	2	US-08-913-994B-1	Sequence 1, Appli
2	79	92.9	20	20	2	US-08-913-994B-6	Sequence 6, Appli
3	65	76.5	128	128	1	US-08-202-047-21	Sequence 21, Appl
4	65	76.5	128	128	2	US-08-964-690-21	Sequence 21, Appl
5	63	74.1	93	93	2	US-09-471-276-821	Sequence 821, App
6	63	74.1	114	114	1	US-08-888-366-8	Sequence 8, Appli
7	63	74.1	114	114	2	US-09-724-409-7	Sequence 7, Appli
8	63	74.1	114	114	2	US-09-724-530-7	Sequence 7, Appli
9	63	74.1	114	114	2	US-09-328-296-7	Sequence 7, Appli
10	63	74.1	121	121	2	US-09-698-705-8	Sequence 8, Appli
11	63	74.1	124	124	2	US-09-257-069-2	Sequence 2, Appli
12	63	74.1	124	124	2	US-10-007-790-2	Sequence 2, Appli
13	63	74.1	140	140	2	US-09-471-276-850	Sequence 850, App
14	63	74.1	222	222	2	US-09-698-705-13	Sequence 13, App
15	63	74.1	243	243	1	US-08-230-843-4	Sequence 4, Appli
16	63	74.1	243	243	1	US-08-636-936-4	Sequence 4, Appli
17	60	70.6	116	116	1	US-08-478-039-79	Sequence 79, Appl
18	60	70.6	116	116	1	US-08-476-349A-79	Sequence 79, Appl
19	60	70.6	117	117	2	US-09-744-176A-4	Sequence 4, Appli
20	60	70.6	119	119	2	US-08-478-039-77	Sequence 77, Appl
21	60	70.6	119	119	1	US-08-476-349A-77	Sequence 77, Appl
22	60	70.6	137	137	3	US-09-674-716B-50	Sequence 50, Appl
23	59	69.4	97	97	2	US-10-194-975-40	Sequence 40, Appl
24	59	69.4	97	97	2	US-10-194-975-49	Sequence 49, Appl
25	59	69.4	97	97	2	US-10-194-975-50	Sequence 50, Appl
26	59	69.4	97	97	2	US-08-896-535-76	Sequence 76, Appl
27	59	69.4		116	2	US-08-545-809A-118	Sequence 118, App
28	59	69.4		116	2	US-09-726-219A-217	Sequence 217, App
29	59	69.4		116	2	US-09-196-522-217	Sequence 217, App
30	59	69.4		116	2	US-09-515-697-118	Sequence 118, App
31	59	69.4		116	3	US-10-072-301A-38	Sequence 38, Appl
32	59	69.4		116	2	US-10-072-301A-56	Sequence 56, Appl
33	59	69.4		117	2	US-10-432-006-5	Sequence 5, Appli
34	59	69.4		123	2	US-08-793-450-4	Sequence 4, Appli
35	59	69.4		139	2	US-09-203-768A-2	Sequence 2, Appli
36	59	69.4		250	3	US-10-072-301A-21	Sequence 21, Appl
37	59	69.4		250	3	US-10-072-301A-29	Sequence 29, Appl
38	59	69.4		472	2	US-08-793-450-8	Sequence 8, Appli
39	58	68.2		76	2	US-08-851-362D-19	Sequence 19, Appl
40	58	68.2		76	3	US-09-472-087-85	Sequence 85, Appl
41	58	68.2		98	2	US-10-194-975-1	Sequence 1, Appli
42	58	68.2		98	3	US-10-194-975-44	Sequence 44, Appl
43	58	68.2		99	2	US-10-194-975-36	Sequence 36, Appl
44	58	68.2		99	2	US-10-194-975-39	Sequence 39, Appl
45	58	68.2		99	2	US-10-330-613A-45	Sequence 45, Appl

ALIGNMENTS

```
RESULT 1
US-08-913-994B-1
; Sequence 1, Application US/08913994B
; Patent No. 6613536
; GENERAL INFORMATION:
;   APPLICANT: MOZES, Edna
;              WAISMAN, Ari
;   TITLE OF INVENTION: SYNTHETIC PEPTIDES AND PHARMACEUTICAL
;                       COMPOSITIONS COMPRISING THEM FOR THE TREATMENT
;                       OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
;   NUMBER OF SEQUENCES: 10
;   CORRESPONDENCE ADDRESS:
;     ADDRESSEE: BROWDY AND NEIMARK
;     STREET: 624 Ninth Street N.W., Ste. 300
;     CITY: Washington
;     STATE: D.C.
;     COUNTRY: United States of America
;     ZIP: 20001
;   COMPUTER READABLE FORM:
;     MEDIUM TYPE: Floppy disk
;     COMPUTER: IBM PC compatible
;     OPERATING SYSTEM: PC-DOS/MS-DOS
;     SOFTWARE: PatentIn Release #1.0, Version #1.30
;   CURRENT APPLICATION DATA:
;     APPLICATION NUMBER: US/08/913,994B
;     FILING DATE: 29-Sep-1997
;   PRIOR APPLICATION DATA:
;     APPLICATION NUMBER: PCT/US96/04206
;     FILING DATE: 27-MAR-1996
;     APPLICATION NUMBER: IL 113,159
;     FILING DATE: 28-MAR-1995
;   ATTORNEY/AGENT INFORMATION:
;     NAME: BROWDY, Roger L.
;     REGISTRATION NUMBER: 25,618
;     REFERENCE/DOCKET NUMBER: MOZES=2
;   TELECOMMUNICATION INFORMATION:
;     TELEPHONE: (202) 628-5197
;     TELEFAX: (202) 737-3528
; INFORMATION FOR SEQ ID NO: 1:
;   SEQUENCE CHARACTERISTICS:
;     LENGTH: 20 amino acids
;     TYPE: amino acid
;     STRANDEDNESS: single
;     TOPOLOGY: linear
;   MOLECULE TYPE: peptide
;   FEATURE:
;     OTHER INFORMATION: /note= Xaa in position 5 is Met, Ala or Val;
;       Xaa in position 6 is Gln, Asp, Glu, or Arg; Xaa in
;       position 7 is Trp or Ala; Xaa in position 8 is Val or Ser;
```

```
;             and Xaa in position 9 is Lys, Glu or Ala.
;  SEQUENCE DESCRIPTION: SEQ ID NO: 1:
US-08-913-994B-1

Query Match             94.1%;  Score 80;  DB 2;  Length 20;
Best Local Similarity  100.0%;  Pred. No. 2e-07;
Matches   20;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy          1 TGYYXXXXQSPEKSLEWIG 20
              ||||||||||||||||
Db          1 TGYYXXXXQSPEKSLEWIG 20

RESULT 2
US-08-913-994B-6
; Sequence 6, Application US/08913994B
; Patent No. 6613536
;   GENERAL INFORMATION:
;     APPLICANT: MOZES, Edna
;                WAISMAN, Ari
;     TITLE OF INVENTION: SYNTHETIC PEPTIDES AND PHARMACEUTICAL
;                COMPOSITIONS COMPRISING THEM FOR THE TREATMENT
;                OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
;   NUMBER OF SEQUENCES: 10
;   CORRESPONDENCE ADDRESS:
;     ADDRESSEE: BROWDY AND NEIMARK
;     STREET: 624 Ninth Street N.W., Ste. 300
;     CITY: Washington
;     STATE: D.C.
;     COUNTRY: United States of America
;     ZIP: 20001
;   COMPUTER READABLE FORM:
;     MEDIUM TYPE: Floppy disk
;     COMPUTER: IBM PC compatible
;     OPERATING SYSTEM: PC-DOS/MS-DOS
;     SOFTWARE: PatentIn Release #1.0, Version #1.30
;   CURRENT APPLICATION DATA:
;     APPLICATION NUMBER: US/08/913,994B
;     FILING DATE: 29-Sep-1997
;   PRIOR APPLICATION DATA:
;     APPLICATION NUMBER: PCT/US96/04206
;     FILING DATE: 27-MAR-1996
;     APPLICATION NUMBER: IL 113,159
;     FILING DATE: 28-MAR-1995
;   ATTORNEY/AGENT INFORMATION:
;     NAME: BROWDY, Roger L.
;     REGISTRATION NUMBER: 25,618
;     REFERENCE/DOCKET NUMBER: MOZES=2
;   TELECOMMUNICATION INFORMATION:
;     TELEPHONE: (202) 628-5197
;     TELEFAX: (202) 737-3528
; INFORMATION FOR SEQ ID NO: 6:
;   SEQUENCE CHARACTERISTICS:
;     LENGTH: 20 amino acids
;     TYPE: amino acid
;     STRANDEDNESS: single
;     TOPOLOGY: linear
;   MOLECULE TYPE: peptide
;   SEQUENCE DESCRIPTION: SEQ ID NO: 6:
US-08-913-994B-6

Query Match             92.9%;  Score 79;  DB 2;  Length 20;
Best Local Similarity   75.0%;  Pred. No. 3.1e-07;
Matches   15;  Conservative   0;  Mismatches   5;  Indels   0;  Gaps   0;

Qy          1 TGYYXXXXQSPEKSLEWIG 20
              |||   |||||||||||||
Db          1 TGYYMQWVKQSPEKSLEWIG 20

RESULT 3
US-08-202-047-21
; Sequence 21, Application US/08202047
```

```
; Patent No. 5800815
;   GENERAL INFORMATION:
;     APPLICANT: CHESNUT, Robert W.
;     APPLICANT: POLLEY, Margaret J.
;     APPLICANT: PAULSON, James C.
;     APPLICANT: JONES, S. Tarran
;     APPLICANT: SALDANHA, Jose W.
;     APPLICANT: BENDIG, Mary M.
;   TITLE OF INVENTION: Antibodies to P-Selectin and Their Uses
;   NUMBER OF SEQUENCES: 45
;   CORRESPONDENCE ADDRESS:
;     ADDRESSEE: Townsend and Townsend Khourie and Crew
;     STREET: One Market Plaza, Steuart Tower, Suite 2000
;     CITY: San Francisco
;     STATE: California
;     COUNTRY: USA
;     ZIP: 94105
;   COMPUTER READABLE FORM:
;     MEDIUM TYPE: Floppy disk
;     COMPUTER: IBM PC compatible
;     OPERATING SYSTEM: PC-DOS/MS-DOS
;     SOFTWARE: PatentIn Release #1.0, Version #1.25
;   CURRENT APPLICATION DATA:
;     APPLICATION NUMBER: US/08/202,047
;     FILING DATE: 25-FEB-1994
;     CLASSIFICATION: 424
;   ATTORNEY/AGENT INFORMATION:
;     NAME: Smith, William M.
;     REGISTRATION NUMBER: 30,223
;     REFERENCE/DOCKET NUMBER: 14137-77
;   TELECOMMUNICATION INFORMATION:
;     TELEPHONE: 415-326-2400
;     TELEFAX: 415-326-2422
; INFORMATION FOR SEQ ID NO: 21:
;   SEQUENCE CHARACTERISTICS:
;     LENGTH: 128 amino acids
;     TYPE: amino acid
;     STRANDEDNESS: single
;     TOPOLOGY: linear
;   MOLECULE TYPE: protein
;   FEATURE:
;     NAME/KEY: Protein
;     LOCATION: 1..128
;     OTHER INFORMATION: /label= MOUSE_IIA
US-08-202-047-21

Query Match             76.5%;  Score 65;  DB 1;  Length 128;
Best Local Similarity   65.0%;  Pred. No. 0.00075;
Matches   13;  Conservative   0;  Mismatches   7;  Indels   0;  Gaps   0;

Qy          1 TGYYXXXXQSPEKSLEWIG 20
              ||  |||||||| |||||
Db         30 TDYYMNWVKQSPGKSLEWIG 49

RESULT 4
US-08-964-690-21
; Sequence 21, Application US/08964690
; Patent No. 6033667
;   GENERAL INFORMATION:
;     APPLICANT: CHESNUT, Robert W.
;     APPLICANT: POLLEY, Margaret J.
;     APPLICANT: PAULSON, James C.
;     APPLICANT: JONES, S. Tarran
;     APPLICANT: SALDANHA, Jose W.
;     APPLICANT: BENDIG, Mary M.
;   TITLE OF INVENTION: Antibodies to P-Selectin and Their Uses
;   NUMBER OF SEQUENCES: 45
;   CORRESPONDENCE ADDRESS:
;     ADDRESSEE: Townsend and Townsend Khourie and Crew
;     STREET: One Market Plaza, Steuart Tower, Suite 2000
;     CITY: San Francisco
;     STATE: California
```

```
;       COUNTRY: USA
;       ZIP: 94105
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE: Floppy disk
;       COMPUTER: IBM PC compatible
;       OPERATING SYSTEM: PC-DOS/MS-DOS
;       SOFTWARE: PatentIn Release #1.0, Version #1.25
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER: US/08/964,690
;       FILING DATE:
;       CLASSIFICATION:
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER: US/08/202,047
;       FILING DATE: 25-FEB-1994
;     ATTORNEY/AGENT INFORMATION:
;       NAME: Smith, William M.
;       REGISTRATION NUMBER: 30,223
;       REFERENCE/DOCKET NUMBER: 14137-77
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE: 415-326-2400
;       TELEFAX: 415-326-2422
;     INFORMATION FOR SEQ ID NO: 21:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH: 128 amino acids
;       TYPE: amino acid
;       STRANDEDNESS: single
;       TOPOLOGY: linear
;     MOLECULE TYPE: protein
;     FEATURE:
;       NAME/KEY: Protein
;       LOCATION: 1..128
;     OTHER INFORMATION: /label= MOUSE_IIA
US-08-964-690-21

Query Match      76.5%;    Score 65;  DB 2;  Length 128;
Best Local Similarity    65.0%;    Pred. No. 0.00075;
Matches   13; Conservative   0;  Mismatches   7;  Indels   0;  Gaps   0;

Qy    1 TGYYXXXXQSPEKSLEWIG 20
         |||  |||||||||
Db   30 TDYYMNWVKQSPGKSLEWIG 49

RESULT 5
US-09-471-276-821
; Sequence 821, Application US/09471276
; Patent No. 6822072
; GENERAL INFORMATION:
;     APPLICANT: Dumas Milne Edwards, J.B.
;     APPLICANT: Duclert A.
;     APPLICANT: Giordano, J.Y.
;     TITLE OF INVENTION: Expressed Sequence Tags and Encoded Human Proteins.
; Patent No. 6822072
;     FILE REFERENCE: GENSET.025CP1
;     CURRENT APPLICATION NUMBER: US/09/471,276
;     CURRENT FILING DATE: 1999-12-21
;     EARLIER APPLICATION NUMBER: 09/057,719
;     EARLIER FILING DATE: 1998-04-09
;     EARLIER APPLICATION NUMBER: 09/069,047
;     EARLIER FILING DATE: 1998-04-28
;     EARLIER APPLICATION NUMBER: PCT/IB99/00712
;     EARLIER FILING DATE: 1999-04-09
;     NUMBER OF SEQ ID NOS: 1622
;     SOFTWARE: Patent.pm
; SEQ ID NO 821
;     LENGTH: 93
;     TYPE: PRT
;     ORGANISM: Homo sapiens
;     FEATURE:
;     NAME/KEY: SIGNAL
;     LOCATION: -19..-1
US-09-471-276-821
```

```
Query Match      74.1%;    Score 63;  DB 2;  Length 93;
Best Local Similarity    65.0%;    Pred. No. 0.0012;
Matches   13; Conservative   0;  Mismatches   7;  Indels   0;  Gaps   0;

Qy    1 TGYYXXXXQSPEKSLEWIG 20
         |||| |||||||||
Db   49 TNYYWSXIRQSPGKGLEWIG 68

RESULT 6
US-08-888-366-8
; Sequence 8, Application US/08888366
; Patent No. 5972656
; GENERAL INFORMATION:
;     APPLICANT: Lopez, Osvaldo
;     APPLICANT: Wylie, Dwane E.
;     APPLICANT: Wagner, Fred W.
;     TITLE OF INVENTION: Mercury Binding Polypeptides and Nucleotides Coding Therefore
;     NUMBER OF SEQUENCES: 39
;     CORRESPONDENCE ADDRESS:
;       ADDRESSEE: Merchant & Gould
;       STREET: 90 South 7th Street, 3100 No. 5972656west Ctr.
;       CITY: Minneapolis
;       STATE: MN
;       COUNTRY: USA
;       ZIP: 55402
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE: Floppy disk
;       COMPUTER: IBM PC compatible
;       OPERATING SYSTEM: PC-DOS/MS-DOS
;       SOFTWARE: PatentIn Release #1.0, Version #1.25
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER: US/08/888,366
;       FILING DATE: 03-JUL-1997
;       CLASSIFICATION: 435
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER: US 08/187,407
;       FILING DATE: 27-JAN-1994
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER: US 07/990,542
;       FILING DATE: 14-DEC-1992
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER: US 07/493,299
;       FILING DATE: 14-MAR-1990
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER: US 07/324,392
;       FILING DATE: 14-MAR-1989
;     ATTORNEY/AGENT INFORMATION:
;       NAME: Carter, Charles G.
;       REGISTRATION NUMBER: 35,093
;       REFERENCE/DOCKET NUMBER: 8648.39USC1
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE: 612-332-5300
;       TELEFAX: 612-332-9081
;     INFORMATION FOR SEQ ID NO: 8:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH: 114 amino acids
;       TYPE: amino acid
;       TOPOLOGY: linear
;     MOLECULE TYPE: protein
US-08-888-366-8

Query Match      74.1%;    Score 63;  DB 1;  Length 114;
Best Local Similarity    65.0%;    Pred. No. 0.0015;
Matches   13; Conservative   0;  Mismatches   7;  Indels   0;  Gaps   0;

Qy    1 TGYYXXXXQSPEKSLEWIG 20
         ||||   |||||||
Db   24 TGYYMHWVKQSHGKSLEWIG 43

RESULT 7
US-09-724-409-7
```

; Sequence 7, Application US/09724409
; Patent No. 6838261
; GENERAL INFORMATION:
; APPLICANT: Siegall, Clay
; APPLICANT: Wahl, Alan
; APPLICANT: Francisco, Joseph
; APPLICANT: Fell, H. Perry
; TITLE OF INVENTION: RECOMBINANT ANTI-CD40 ANTIBODY AND USES THEREOF
; FILE REFERENCE: 9632-005
; CURRENT APPLICATION NUMBER: US/09/724,409
; CURRENT FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: US/09/328,296
; PRIOR FILING DATE: 1999-06-08
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 7
; LENGTH: 114
; TYPE: PRT
; ORGANISM: Mus musculus
US-09-724-409-7

Query Match 74.1%; Score 63; DB 2; Length 114;
Best Local Similarity 65.0%; Pred. No. 0.0015;
Matches 13; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

Qy 1 TGYYXXXXQSPEKSLEWIG 20
   |||| || |||||||
Db 30 TGYYIHWVKQSHGKSLEWIG 49

RESULT 8
US-09-724-530-7
; Sequence 7, Application US/09724530
; Patent No. 6843989
; GENERAL INFORMATION:
; APPLICANT: Siegall, Clay
; APPLICANT: Wahl, Alan
; APPLICANT: Francisco, Joseph
; APPLICANT: Fell, H. Perry
; TITLE OF INVENTION: RECOMBINANT ANTI-CD40 ANTIBODY AND USES THEREOF
; FILE REFERENCE: 9632-005
; CURRENT APPLICATION NUMBER: US/09/724,530
; CURRENT FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: CURRENT APPLICATION NUMBER: US/09/328,296
; PRIOR FILING DATE: CURRENT FILING DATE: 1999-06-08
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 7
; LENGTH: 114
; TYPE: PRT
; ORGANISM: Mus musculus
US-09-724-530-7

Query Match 74.1%; Score 63; DB 2; Length 114;
Best Local Similarity 65.0%; Pred. No. 0.0015;
Matches 13; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

Qy 1 TGYYXXXXQSPEKSLEWIG 20
   |||| || |||||||
Db 30 TGYYIHWVKQSHGKSLEWIG 49

RESULT 9
US-09-328-296-7
; Sequence 7, Application US/09328296
; Patent No. 6946129
; GENERAL INFORMATION:
; APPLICANT: Siegall, Clay
; APPLICANT: Wahl, Alan
; APPLICANT: Francisco, Joseph
; APPLICANT: Fell, H. Perry
; TITLE OF INVENTION: RECOMBINANT ANTI-CD40 ANTIBODY AND USES THEREOF
; FILE REFERENCE: 9632-005
; CURRENT APPLICATION NUMBER: US/09/328,296
; CURRENT FILING DATE: 1999-06-08
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 7
; LENGTH: 114
; TYPE: PRT
; ORGANISM: Mus musculus
US-09-328-296-7

Query Match 74.1%; Score 63; DB 2; Length 114;
Best Local Similarity 65.0%; Pred. No. 0.0015;
Matches 13; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

Qy 1 TGYYXXXXQSPEKSLEWIG 20
   |||| || |||||||
Db 30 TGYYIHWVKQSHGKSLEWIG 49

RESULT 10
US-09-698-705-8
; Sequence 8, Application US/09698705
; Patent No. 6824780
; GENERAL INFORMATION:
; APPLICANT: Devaux, B.
; APPLICANT: Keller, G.
; APPLICANT: Koeppen, H.
; APPLICANT: Lasky, L.
; TITLE OF INVENTION: Anti-Tumor Antibody Compositions and Methods of Use
; FILE REFERENCE: P1777R1
; CURRENT APPLICATION NUMBER: US/09/698,705
; CURRENT FILING DATE: 2000-10-27
; PRIOR APPLICATION NUMBER: US 60/162,558
; PRIOR FILING DATE: 1999-10-29
; PRIOR APPLICATION NUMBER: US 60/182,872
; PRIOR FILING DATE: 2000-02-16
; NUMBER OF SEQ ID NOS: 25
; SEQ ID NO 8
; LENGTH: 121
; TYPE: PRT
; ORGANISM: Mus musculus
US-09-698-705-8

Query Match 74.1%; Score 63; DB 2; Length 121;
Best Local Similarity 65.0%; Pred. No. 0.0016;
Matches 13; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

Qy 1 TGYYXXXXQSPEKSLEWIG 20
   |||| || |||||||
Db 30 TGYYIHWVKQSHGKSLEWIG 49

RESULT 11
US-09-257-069-2
; Sequence 2, Application US/09257069
; Patent No. 6348580
; GENERAL INFORMATION:
; APPLICANT: Medical & Biological Laboratories Co.,Ltd.
; TITLE OF INVENTION: Monoclonal Antibody Specific for
; TITLE OF INVENTION: Phosphatidylinositol-3,4,5-Triphosphate
; FILE REFERENCE: M3-008-US
; CURRENT APPLICATION NUMBER: US/09/257,069
; CURRENT FILING DATE: 1999-02-24
; PRIOR APPLICATION NUMBER: JP 1998-252921
; PRIOR FILING DATE: 1998-09-07
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 2
; LENGTH: 124
; TYPE: PRT
; ORGANISM: Mus musculus
US-09-257-069-2

Matches   12;   Conservative   0;   Mismatches   7;   Indels   0;   Gaps   0;

```
Qy    2 GYYXXXXQSPEKSLEWIG 20
          |||  ||||||||
Db   57 GYYWSWIRQSPGKGLEWIG 75
```

RESULT 14
US-09-698-705-13
; Sequence 13, Application US/09698705
; Patent No. 6824780
; GENERAL INFORMATION:
; APPLICANT: Devaux, B.
; APPLICANT: Keller, G.
; APPLICANT: Koeppen, H.
; APPLICANT: Lasky, L.
; TITLE OF INVENTION: Anti-Tumor Antibody Compositions and Methods of Use
; FILE REFERENCE: P1777R1
; CURRENT APPLICATION NUMBER: US/09/698,705
; CURRENT FILING DATE: 2000-10-27
; PRIOR APPLICATION NUMBER: US 60/162,558
; PRIOR FILING DATE: 1999-10-29
; PRIOR APPLICATION NUMBER: US 60/182,872
; PRIOR FILING DATE: 2000-02-16
; NUMBER OF SEQ ID NOS: 25
; SEQ ID NO 13
; LENGTH: 222
; TYPE: PRT
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: sequence is chimeric mouse/human
US-09-698-705-13

Query Match   74.1%;   Score 63;   DB 2;   Length 222;
Best Local Similarity 65.0%;   Pred. No. 0.0031;
Matches   13;   Conservative   0;   Mismatches   7;   Indels   0;   Gaps   0;

```
Qy    1 TGYYXXXXQSPEKSLEWIG 20
          ||||  |||||||
Db   30 TGYYIHWVKQSHGKSLEWIG 49
```

RESULT 15
US-08-230-843-4
; Sequence 4, Application US/08230843
; Patent No. 5582826
; GENERAL INFORMATION:
; APPLICANT: SHIMAMURA, TOSHIRO
; APPLICANT: HAMURO, JUNJI
; APPLICANT: NAKAZAWA, HARUMI
; APPLICANT: KANAYAMA, YUKA
; APPLICANT: SUGAMURA, KAZUO
; APPLICANT: TAKESHITA, TOSHIKAZU
; TITLE OF INVENTION: IMMUNOSUPPRESSANT
; NUMBER OF SEQUENCES: 12
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT,
; ADDRESSEE: P.C.
; STREET: 1755 S. Jefferson Davis Highway, Suite 400
; CITY: Arlington
; STATE: Virginia
; COUNTRY: U.S.A.
; ZIP: 22202
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/230,843
; FILING DATE: 21-APR-1994
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:

Query Match   74.1%;   Score 63;   DB 2;   Length 124;
Best Local Similarity 65.0%;   Pred. No. 0.0016;
Matches   13;   Conservative   0;   Mismatches   7;   Indels   0;   Gaps   0;

```
Qy    1 TGYYXXXXQSPEKSLEWIG 20
          ||||  |||||||
Db   30 TGYYMHWVKQSHGKSLEWIG 49
```

RESULT 12
US-10-007-790-2
; Sequence 2, Application US/10007790
; Patent No. 6818408
; GENERAL INFORMATION:
; APPLICANT: Medical & Biological Laboratories Co.Ltd.
; TITLE OF INVENTION: Monoclonal Antibody Specific for
; TITLE OF INVENTION: Phosphatidylinositol-3,4,5-Triphosphate
; FILE REFERENCE: M3-008-US
; CURRENT APPLICATION NUMBER: US/10/007,790
; CURRENT FILING DATE: 2001-11-13
; PRIOR APPLICATION NUMBER: US/09/257,069
; PRIOR FILING DATE: 1999-02-24
; PRIOR APPLICATION NUMBER: JP 1998-252921
; PRIOR FILING DATE: 1998-09-07
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 2
; LENGTH: 124
; TYPE: PRT
; ORGANISM: Mus musculus
US-10-007-790-2

Query Match   74.1%;   Score 63;   DB 2;   Length 124;
Best Local Similarity 65.0%;   Pred. No. 0.0016;
Matches   13;   Conservative   0;   Mismatches   7;   Indels   0;   Gaps   0;

```
Qy    1 TGYYXXXXQSPEKSLEWIG 20
          ||||  |||||||
Db   30 TGYYMHWVKQSHGKSLEWIG 49
```

RESULT 13
US-09-471-276-850
; Sequence 850, Application US/09471276
; Patent No. 6822072
; GENERAL INFORMATION:
; APPLICANT: Dumas Milne Edwards, J.B.
; APPLICANT: Duclert A.
; APPLICANT: Giordano, J.Y.
; TITLE OF INVENTION: Expressed Sequence Tags and Encoded Human Proteins.
; Patent No. 6822072
; FILE REFERENCE: GENSET.025CP1
; CURRENT APPLICATION NUMBER: US/09/471,276
; CURRENT FILING DATE: 1999-12-21
; EARLIER APPLICATION NUMBER: 09/057,719
; EARLIER FILING DATE: 1998-04-28
; EARLIER FILING DATE: 1998-04-09
; EARLIER APPLICATION NUMBER: 09/069,047
; EARLIER FILING DATE: 1998-04-28
; EARLIER APPLICATION NUMBER: PCT/IB99/00712
; EARLIER FILING DATE: 1999-04-09
; NUMBER OF SEQ ID NOS: 1622
; SOFTWARE: Patent.pm
; SEQ ID NO 850
; LENGTH: 140
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: SIGNAL
; LOCATION: -26..-1
US-09-471-276-850

Query Match   74.1%;   Score 63;   DB 2;   Length 140;
Best Local Similarity 63.2%;   Pred. No. 0.0019;

```
;       APPLICATION NUMBER:  JP 094491/1993
;       FILING DATE: 21-APR-1993
;  PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  JP 036065/1994
;       FILING DATE: 07-MAR-1994
;  ATTORNEY/AGENT INFORMATION:
;       NAME:  Oblon, No. 558282  6man F.
;       REGISTRATION NUMBER:  24,618
;       REFERENCE/DOCKET NUMBER:  0010-0674-0X
;  TELECOMUNICATION INFORMATION:
;       TELEPHONE:  (703) 413-3000
;       TELEFAX:  (703) 413-2220
;       TELEX:  248855 OPAT UR
;  INFORMATION FOR SEQ ID NO:  4:
;  SEQUENCE CHARACTERISTICS:
;       LENGTH:  243 amino acids
;       TYPE:  amino acid
;       TOPOLOGY:  linear
;  MOLECULE TYPE:  protein
US-08-230-843-4

Query Match          74.1%;  Score 63;  DB 1;  Length 243;
Best Local Similarity   65.0%;  Pred. No. 0.0035;
Matches   13;  Conservative   0;  Mismatches   7;  Indels   0;  Gaps   0;

Qy     1 TGYYXXXXQSPEKSLEWIG 20
           |||  ||  || |||||||
Db   152 TGYYMHWVKQSHVKSLEWIG 171

Search completed: October 18, 2006, 19:50:49
Job time : 25.1237 secs
```

```
                Copyright   GenCore version 5.1.9
                Copyright (c) 1993 - 2006 Biocceleration Ltd.

OM protein - protein search, using sw model

Run on:      October 18, 2006, 20:43:15  ; Search time 14.3299 Seconds
                                          (without alignments)
                                          112.851 Million cell updates/sec

Title:           US-10-620-621-1
Perfect score:   85
Sequence:        1 TGYYXXXXQSPEKSLEWIG 20
Scoring table:   BLOSUM62
                 Gapop 10.0 , Gapext 0.5
Searched:        300827 seqs, 80857292 residues

Total number of hits satisfying chosen parameters:        300827

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
                 Maximum Match 100%
                 Listing first 45 summaries

Database :      Published Applications AA New:*
                1: /EMC_Celerra_SIDS3/ptcdata/2/pubpaa/US09_NEW_PUB.pep:*
                2: /EMC_Celerra_SIDS3/ptcdata/2/pubpaa/US06_NEW_PUB.pep:*
                3: /EMC_Celerra_SIDS3/ptcdata/2/pubpaa/US07_NEW_PUB.pep:*
                4: /EMC_Celerra_SIDS3/ptcdata/2/pubpaa/US08_NEW_PUB.pep:*
                5: /EMC_Celerra_SIDS3/ptcdata/2/pubpaa/PCT_NEW_PUB.pep:*
                6: /EMC_Celerra_SIDS3/ptcdata/2/pubpaa/US10_NEW_PUB.pep:*
                7: /EMC_Celerra_SIDS3/ptcdata/2/pubpaa/US11_NEW_PUB.pep:*
                8: /EMC_Celerra_SIDS3/ptcdata/2/pubpaa/US60_NEW_PUB.pep:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

                                   SUMMARIES

Result           %
No.    Score  Match  Length DB  ID                     Description
----   -----  -----  ------ --   --                     -----------
  1     79    92.9    470    6   US-10-526-741-12       Sequence 12, Appl
  2     79    92.9    470    7   US-11-414-676-12       Sequence 12, Appl
  3     64    75.3    120    7   US-11-221-902-18       Sequence 18, Appl
  4     64    75.3    447    7   US-11-221-902-8        Sequence 8, Appli
  5     63    74.1    139    7   US-11-221-902-14       Sequence 14, Appl
  6     63    74.1    447    7   US-11-221-902-4        Sequence 4, Appli
  7     63    74.1    447    7   US-11-221-902-6        Sequence 6, Appli
  8     63    74.1    450    7   US-11-221-902-2        Sequence 2, Appli
  9     61    71.8    491    7   US-11-293-697-4290     Sequence 4290, Ap
 10     60    70.6    117    6   US-10-972-296-4        Sequence 4, Appli
 11     59    69.4     78    1   US-09-784-950-85       Sequence 85, Appl
 12     59    69.4     92    1   US-09-784-950-86       Sequence 86, Appl
 13     59    69.4     92    1   US-09-784-950-87       Sequence 87, Appl
 14     59    69.4    116    7   US-11-241-154-6        Sequence 6, Appli
 15     59    69.4    124    7   US-11-111-688-1        Sequence 1, Appli
 16     59    69.4    126    7   US-11-111-688-55       Sequence 55, Appl
 17     59    69.4    128    7   US-11-094-132-67       Sequence 67, Appl
 18     59    69.4    139    7   US-11-413-563-2        Sequence 2, Appli
 19     59    69.4    190    1   US-09-784-950-33       Sequence 33, Appl
 20     59    69.4    202    1   US-09-784-950-31       Sequence 31, Appl
 21     59    69.4    205    1   US-09-784-950-23       Sequence 23, Appl
 22     58    68.2     76    7   US-11-267-860-35       Sequence 35, Appl
 23     58    68.2     98    7   US-11-221-902-52       Sequence 52, Appl
 24     58    68.2     98    7   US-11-221-902-64       Sequence 64, Appl
 25     58    68.2    118    6   US-10-981-300-51       Sequence 51, Appl
```

```
 26     58    68.2    120    7   US-11-221-902-19       Sequence 19, Appl
 27     58    68.2    120    7   US-11-221-902-21       Sequence 21, Appl
 28     58    68.2    121    7   US-11-221-917-66       Sequence 66, Appl
 29     58    68.2    121    7   US-11-211-917-82       Sequence 82, Appl
 30     58    68.2    121    7   US-11-211-917-98       Sequence 98, Appl
 31     58    68.2    122    7   US-11-211-917-110      Sequence 110, App
 32     58    68.2    126    7   US-11-211-917-42       Sequence 42, Appl
 33     58    68.2    149    7   US-11-355-464-13       Sequence 13, Appl
 34     58    68.2    149    7   US-11-355-464-16       Sequence 16, Appl
 35     58    68.2    150    7   US-11-324-769-14       Sequence 14, Appl
 36     58    68.2    157    7   US-11-267-860-67       Sequence 67, Appl
 37     58    68.2    247    6   US-10-539-402-10       Sequence 10, Appl
 38     58    68.2    447    7   US-11-221-902-10       Sequence 10, Appl
 39     58    68.2    447    7   US-11-221-902-12       Sequence 12, Appl
 40     58    68.2    447    7   US-11-221-902-84       Sequence 84, Appl
 41     58    68.2    466    7   US-11-211-917-70       Sequence 70, Appl
 42     58    68.2    466    7   US-11-211-917-86       Sequence 86, Appl
 43     58    68.2    471    7   US-11-211-917-46       Sequence 46, Appl
 44     57    67.1     95    7   US-11-267-860-53       Sequence 53, Appl
 45     57    67.1     96    7   US-11-267-860-76       Sequence 76, Appl

                                ALIGNMENTS

RESULT 1
US-10-526-741-12
; Sequence 12, Application US/10526741
; Publication No. US2006167232A1
; GENERAL INFORMATION:
;  APPLICANT:   ABURATANI, Hiroyuki
;  APPLICANT:   MIDORIKAWA, Yutaka
;  APPLICANT:   NAKANO, Kiyotaka
;  APPLICANT:   OHIZUMI, Iwao
;  APPLICANT:   ITO, Yukio
;  APPLICANT:   TOKITA, Susumu
;  TITLE OF INVENTION: ANTIBODY AGAINST SOLUBLE N-TERMINAL PEPTIDE OR C-TERMINAL PEPTIDE
;  TITLE OF INVENTION:  PRESENT IN BLOOD
;  FILE REFERENCE:
;  CURRENT APPLICATION NUMBER: US/10/526,741
;  CURRENT FILING DATE:  2005-03-04
;  PRIOR APPLICATION NUMBER: PCT/JP02/08999
;  PRIOR FILING DATE: 2002-09-04
;  NUMBER OF SEQ ID NOS: 24
;  SOFTWARE: PatentIn Ver. 2.1
;
; SEQ ID NO 12
;  LENGTH: 470
;  TYPE: PRT
;  ORGANISM: Artificial Sequence
;  FEATURE:
;  OTHER INFORMATION: Description of Artificial Sequence: Mouse-human
;  OTHER INFORMATION: chimeric antibody (M1E07 H chain)
US-10-526-741-12

  Query Match             92.9%;  Score 79;  DB 6;  Length 470;
  Best Local Similarity   75.0%;  Pred. No. 4.1e-06;
  Matches   15;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy          1 TGYYXXXXQSPEKSLEWIG 20
              ||||     ||||||||||
Db         49 TGYYMHVKQSPEKSLEWIG 68

RESULT 2
US-11-414-676-12
; Sequence 12, Application US/11414676
; Publication No. US2006018851OA1
; GENERAL INFORMATION:
;  APPLICANT:   ABURATANI, Hiroyuki
;  APPLICANT:   MIDORIKAWA, Yutaka
;  APPLICANT:   NAKANO, Kiyotaka
;  APPLICANT:   OHIZUMI, Iwao
;  APPLICANT:   ITO, Yukio
```

; APPLICANT: TOKITA, Susumu
; TITLE OF INVENTION: ANTIBODY AGAINST SOLUBLE N-TERMINAL PEPTIDE OR C-TERMINAL PEPTIDE
; TITLE OF INVENTION: PRESENT IN BLOOD
; FILE REFERENCE:
; CURRENT APPLICATION NUMBER: US/11/414,676
; CURRENT FILING DATE: 2006-04-28
; PRIOR APPLICATION NUMBER: US/10/526,741
; PRIOR FILING DATE: 2005-11-14
; PRIOR APPLICATION NUMBER: PCT/JP02/08999
; PRIOR FILING DATE: 2002-09-04
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 12
; LENGTH: 470
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Mouse-human
; OTHER INFORMATION: chimeric antibody (M1E07 H chain)
US-11-414-676-12

Query Match   92.9%;   Score 79;   DB 7;   Length 470;
Best Local Similarity   75.0%;   Pred. No. 4.1e-06;
Matches   15;   Conservative   0;   Mismatches   5;   Indels   0;   Gaps   0;

Qy   1 TGYYXXXXQSPEKSLEWIG 20
          |||| ||||||||
Db   49 TGYYMHWKQSPEKSLEWIG 68

RESULT 3
US-11-221-902-18
; Sequence 18, Application US/11221902
; Publication No. US20060088522A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: HUMANIZED ANTI-5T4 ANTIBODIES AND ANTI-5T4/CALICHEAMICIN CONJUGAT
; FILE REFERENCE: 040000-0317285
; CURRENT APPLICATION NUMBER: US/11/221,902
; CURRENT FILING DATE: 2005-09-09
; NUMBER OF SEQ ID NOS: 89
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 18
; LENGTH: 120
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: artificial sequence is derived from mouse and human antibody
; OTHER INFORMATION: sequences
US-11-221-902-18

Query Match   75.3%;   Score 64;   DB 7;   Length 120;
Best Local Similarity   60.0%;   Pred. No. 0.00046;
Matches   12;   Conservative   1;   Mismatches   7;   Indels   0;   Gaps   0;

Qy   1 TGYYXXXXQSPEKSLEWIG 20
          ||| : |||||
Db   30 TGYYMHWKQSPGQGLEWIG 49

RESULT 4
US-11-221-902-8
; Sequence 8, Application US/11221902
; Publication No. US20060088522A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: HUMANIZED ANTI-5T4 ANTIBODIES AND ANTI-5T4/CALICHEAMICIN CONJUGAT
; FILE REFERENCE: 040000-0317285
; CURRENT APPLICATION NUMBER: US/11/221,902
; CURRENT FILING DATE: 2005-09-09
; NUMBER OF SEQ ID NOS: 89
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 8

; LENGTH: 447
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: artificial sequence is derived from mouse and human antibody
; OTHER INFORMATION: sequences
; FEATURE:
; NAME/KEY: MISC_FEATURE
; LOCATION: (1)..(120)
; OTHER INFORMATION: heavy chain variable region
US-11-221-902-8

Query Match   75.3%;   Score 64;   DB 7;   Length 447;
Best Local Similarity   60.0%;   Pred. No. 0.0018;
Matches   12;   Conservative   1;   Mismatches   7;   Indels   0;   Gaps   0;

Qy   1 TGYYXXXXQSPEKSLEWIG 20
          ||| : |||||
Db   30 TGYYMHWKQSPGQGLEWIG 49

RESULT 5
US-11-221-902-14
; Sequence 14, Application US/11221902
; Publication No. US20060088522A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: HUMANIZED ANTI-5T4 ANTIBODIES AND ANTI-5T4/CALICHEAMICIN CONJUGAT
; FILE REFERENCE: 040000-0317285
; CURRENT APPLICATION NUMBER: US/11/221,902
; CURRENT FILING DATE: 2005-09-09
; NUMBER OF SEQ ID NOS: 89
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 14
; LENGTH: 139
; TYPE: PRT
; ORGANISM: Mus musculus
; FEATURE:
; NAME/KEY: MISC_FEATURE
; LOCATION: (1)..(19)
; OTHER INFORMATION: leader sequence
; FEATURE:
; NAME/KEY: MATURE PEPTIDE
; LOCATION: (20)..(139)
US-11-221-902-14

Query Match   74.1%;   Score 63;   DB 7;   Length 139;
Best Local Similarity   65.0%;   Pred. No. 0.0008;
Matches   13;   Conservative   0;   Mismatches   7;   Indels   0;   Gaps   0;

Qy   1 TGYYXXXXQSPEKSLEWIG 20
          |||| ||||||
Db   49 TGYYMHWKQSHGKSLEWIG 68

RESULT 6
US-11-221-902-4
; Sequence 4, Application US/11221902
; Publication No. US20060088522A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: HUMANIZED ANTI-5T4 ANTIBODIES AND ANTI-5T4/CALICHEAMICIN CONJUGAT
; FILE REFERENCE: 040000-0317285
; CURRENT APPLICATION NUMBER: US/11/221,902
; CURRENT FILING DATE: 2005-09-09
; NUMBER OF SEQ ID NOS: 89
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 4
; LENGTH: 447
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: artificial sequence is derived from mouse and human antibody

```
; OTHER INFORMATION: sequences
;   FEATURE:
;   NAME/KEY: MISC_FEATURE
;   LOCATION: (1)..(120)
;   OTHER INFORMATION: heavy chain variable region
US-11-221-902-4

Query Match     74.1%;  Score 63;  DB 7;  Length 447;
Best Local Similarity   65.0%;  Pred. No. 0.0028;
Matches    13;  Conservative    0;  Mismatches    7;  Indels    0;  Gaps    0;

Qy    1 TGYYXXXXQSPEKSLEWIG 20
        ||||   ||||||
Db   30 TGYYMHWVKQSHGKSLEWIG 49

RESULT 7
US-11-221-902-6
; Sequence 6, Application US/11221902
; Publication No. US20060088522A1
; GENERAL INFORMATION:
;   APPLICANT: Wyeth
;   TITLE OF INVENTION: HUMANIZED ANTI-5T4 ANTIBODIES AND ANTI-5T4/CALICHEAMICIN CONJUGAT
;   FILE REFERENCE: 040000-0317285
;   CURRENT APPLICATION NUMBER: US/11/221,902
;   CURRENT FILING DATE: 2005-09-09
;   NUMBER OF SEQ ID NOS: 89
;   SOFTWARE: PatentIn version 3.3
; SEQ ID NO 6
;   LENGTH: 447
;   TYPE: PRT
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: artificial sequence is derived from mouse and human antibody
;   OTHER INFORMATION: sequences
;   FEATURE:
;   NAME/KEY: MISC_FEATURE
;   LOCATION: (1)..(120)
;   OTHER INFORMATION: heavy chain variable region
US-11-221-902-6

Query Match     74.1%;  Score 63;  DB 7;  Length 447;
Best Local Similarity   65.0%;  Pred. No. 0.0028;
Matches    13;  Conservative    0;  Mismatches    7;  Indels    0;  Gaps    0;

Qy    1 TGYYXXXXQSPEKSLEWIG 20
        ||||   ||||||
Db   30 TGYYMHWVKQSHGKSLEWIG 49

RESULT 8
US-11-221-902-2
; Sequence 2, Application US/11221902
; Publication No. US20060088522A1
; GENERAL INFORMATION:
;   APPLICANT: Wyeth
;   TITLE OF INVENTION: HUMANIZED ANTI-5T4 ANTIBODIES AND ANTI-5T4/CALICHEAMICIN CONJUGAT
;   FILE REFERENCE: 040000-0317285
;   CURRENT APPLICATION NUMBER: US/11/221,902
;   CURRENT FILING DATE: 2005-09-09
;   NUMBER OF SEQ ID NOS: 89
;   SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2
;   LENGTH: 450
;   TYPE: PRT
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: artificial sequence is derived from mouse and human antibody
;   OTHER INFORMATION: sequences
;   FEATURE:
;   NAME/KEY: MISC_FEATURE
;   LOCATION: (1)..(120)
;   OTHER INFORMATION: heavy chain variable region
US-11-221-902-2

Query Match     74.1%;  Score 63;  DB 7;  Length 450;
Best Local Similarity   65.0%;  Pred. No. 0.0028;
Matches    13;  Conservative    0;  Mismatches    7;  Indels    0;  Gaps    0;

Qy    1 TGYYXXXXQSPEKSLEWIG 20
        ||||   ||||||
Db   30 TGYYMHWVKQSHGKSLEWIG 49

RESULT 9
US-11-293-697-4290
; Sequence 4290, Application US/11293697
; Publication No. US20060105376A1
; GENERAL INFORMATION:
;   APPLICANT: HELIX RESEARCH INSTITUTE
;   TITLE OF INVENTION: Novel full length cDNA
;   FILE REFERENCE: H1-A0106
;   CURRENT APPLICATION NUMBER: US/11/293,697
;   CURRENT FILING DATE: 2005-12-05
;   PRIOR APPLICATION NUMBER: US/10/108,260
;   PRIOR FILING DATE: 2002-03-28
;   NUMBER OF SEQ ID NOS: 5458
;   SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4290
;   LENGTH: 491
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-11-293-697-4290

Query Match     71.8%;  Score 61;  DB 7;  Length 491;
Best Local Similarity   61.1%;  Pred. No. 0.0069;
Matches    11;  Conservative    1;  Mismatches    6;  Indels    0;  Gaps    0;

Qy    2 GYYXXXXQSPEKSLEWI 19
        |||   |||:| ||||
Db   50 GYYWAWIRQSPDKGLEWI 67

RESULT 10
US-10-972-296-4
; Sequence 4, Application US/10972296
; Publication No. US20060153833A1
; GENERAL INFORMATION:
;   APPLICANT: Connex-Gesellschaft zur Optimierung von Forschung und
;   APPLICANT:   Entwicklung mbH
;   APPLICANT:   INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
;   APPLICANT:    (I.N.S.E.R.M)
;   TITLE OF INVENTION: Anti Hepatitis C virus antibody and uses therof
;   FILE REFERENCE: b3030pct
;   CURRENT APPLICATION NUMBER: US/10/972,296
;   CURRENT FILING DATE: 2004-10-25
;   PRIOR APPLICATION NUMBER: US/09/744,176
;   PRIOR FILING DATE: 2001-07-20
;   PRIOR APPLICATION NUMBER: ep 98 11 35 95.7
;   PRIOR FILING DATE: 1998-07-21
;   NUMBER OF SEQ ID NOS: 22
;   SOFTWARE: PatentIn version 3.2
; SEQ ID NO 4
;   LENGTH: 117
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-10-972-296-4

Query Match     70.6%;  Score 60;  DB 6;  Length 117;
Best Local Similarity   55.0%;  Pred. No. 0.0023;
Matches    11;  Conservative    2;  Mismatches    7;  Indels    0;  Gaps    0;

Qy    1 TGYYXXXXQSPEKSLEWIG 20
        |||:   ||||||
Db   30 SGYFWTWIRQSPGKGLEWIG 49
```

RESULT 11
US-09-784-950-85
; Sequence 85, Application US/09784950
; Publication No. US20060104974A1
; GENERAL INFORMATION:
; APPLICANT: Davis, Geoffrey C.
; APPLICANT: Blacher, Russell W.
; APPLICANT: Corvalan, Jose R.
; APPLICANT: Culwell, Alan R.
; APPLICANT: Green, Larry L.
; APPLICANT: Hales, Joanna
; APPLICANT: Havrilla, Nancy
; APPLICANT: Ivanov, Vladimir E.
; APPLICANT: Lipani, John A.
; APPLICANT: Liu, Qiang
; APPLICANT: Weber, Richard F.
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Abgenix, Inc.
; TITLE OF INVENTION: CD147 BINDING MOLECULES AS THERAPEUTICS
; FILE REFERENCE: ABX-CBL/CD147
; CURRENT APPLICATION NUMBER: US/09/784,950
; CURRENT FILING DATE: 2001-02-15
; PRIOR APPLICATION NUMBER: PCT/US99/04583
; PRIOR FILING DATE: 1999-03-03
; PRIOR APPLICATION NUMBER: 09/034,607
; PRIOR APPLICATION NUMBER: 09/244,253
; PRIOR FILING DATE: 1998-03-03
; PRIOR FILING DATE: 1999-02-03
; NUMBER OF SEQ ID NOS: 105
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 85
; LENGTH: 78
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-784-950-85

Query Match   69.4%; Score 59; DB 1; Length 78;
Best Local Similarity   55.0%; Pred. No. 0.0022;
Matches   11; Conservative   1; Mismatches   8; Indels   0; Gaps   0;

Qy   1 TGYYXXXXQSPEKSLEWIG 20
            :||| ||||||||||
Db   11 SGYYWSWIRQPPGKGLEWIG 30

RESULT 12
US-09-784-950-86
; Sequence 86, Application US/09784950
; Publication No. US20060104974A1
; GENERAL INFORMATION:
; APPLICANT: Davis, Geoffrey C.
; APPLICANT: Blacher, Russell W.
; APPLICANT: Corvalan, Jose R.
; APPLICANT: Culwell, Alan R.
; APPLICANT: Green, Larry L.
; APPLICANT: Hales, Joanna
; APPLICANT: Havrilla, Nancy
; APPLICANT: Ivanov, Vladimir E.
; APPLICANT: Lipani, John A.
; APPLICANT: Liu, Qiang
; APPLICANT: Weber, Richard F.
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Abgenix, Inc.
; TITLE OF INVENTION: CD147 BINDING MOLECULES AS THERAPEUTICS
; FILE REFERENCE: ABX-CBL/CD147
; CURRENT APPLICATION NUMBER: US/09/784,950
; CURRENT FILING DATE: 2001-02-15
; PRIOR APPLICATION NUMBER: PCT/US99/04583
; PRIOR FILING DATE: 1999-03-03
; PRIOR APPLICATION NUMBER: 09/034,607
; PRIOR FILING DATE: 1998-03-03
; PRIOR APPLICATION NUMBER: 09/244,253

; PRIOR FILING DATE: 1999-02-03
; NUMBER OF SEQ ID NOS: 105
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 86
; LENGTH: 92
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-784-950-86

Query Match   69.4%; Score 59; DB 1; Length 92;
Best Local Similarity   55.0%; Pred. No. 0.0027;
Matches   11; Conservative   1; Mismatches   8; Indels   0; Gaps   0;

Qy   1 TGYYXXXXQSPEKSLEWIG 20
            :||| ||||||||||
Db   11 SGYYWSWIRQPPGKGLEWIG 30

RESULT 13
US-09-784-950-87
; Sequence 87, Application US/09784950
; Publication No. US20060104974A1
; GENERAL INFORMATION:
; APPLICANT: Davis, Geoffrey C.
; APPLICANT: Blacher, Russell W.
; APPLICANT: Corvalan, Jose R.
; APPLICANT: Culwell, Alan R.
; APPLICANT: Green, Larry L.
; APPLICANT: Hales, Joanna
; APPLICANT: Havrilla, Nancy
; APPLICANT: Ivanov, Vladimir E.
; APPLICANT: Lipani, John A.
; APPLICANT: Liu, Qiang
; APPLICANT: Weber, Richard F.
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Abgenix, Inc.
; TITLE OF INVENTION: CD147 BINDING MOLECULES AS THERAPEUTICS
; FILE REFERENCE: ABX-CBL/CD147
; CURRENT APPLICATION NUMBER: US/09/784,950
; CURRENT FILING DATE: 2001-02-15
; PRIOR APPLICATION NUMBER: PCT/US99/04583
; PRIOR FILING DATE: 1999-03-03
; PRIOR APPLICATION NUMBER: 09/034,607
; PRIOR FILING DATE: 1998-03-03
; PRIOR APPLICATION NUMBER: 09/244,253
; PRIOR FILING DATE: 1999-02-03
; NUMBER OF SEQ ID NOS: 105
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 87
; LENGTH: 92
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-784-950-87

Query Match   69.4%; Score 59; DB 1; Length 92;
Best Local Similarity   55.0%; Pred. No. 0.0027;
Matches   11; Conservative   1; Mismatches   8; Indels   0; Gaps   0;

Qy   1 TGYYXXXXQSPEKSLEWIG 20
            :||| ||||||||||
Db   11 SGYYWSWIRQPPGKGLEWIG 30

RESULT 14
US-11-241-154-6
; Sequence 6, Application US/11241154
; Publication No. US20060177442A1
; GENERAL INFORMATION:
; APPLICANT: Tibor KELER
; TITLE OF INVENTION: METHOD OF TREATING CD30 POSITIVE LYMPHOMAS
; FILE REFERENCE: MXI-327
; CURRENT APPLICATION NUMBER: US/11/241,154
; CURRENT FILING DATE: 2005-09-30

```
;  PRIOR APPLICATION NUMBER: 60/615284
;  PRIOR FILING DATE: 2004-10-01
;  NUMBER OF SEQ ID NOS: 53
;  SOFTWARE: FastSEQ for Windows Version 4.0
;  SEQ ID NO 6
;   LENGTH: 116
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-11-241-154-6

Query Match          69.4%;   Score 59;  DB 7;  Length 116;
Best Local Similarity   55.0%;   Pred. No. 0.0034;
Matches   11;  Conservative   1;  Mismatches   8;  Indels   0;  Gaps   0;

Qy        1 TGYXXXXXQSPEKSLEWIG 20
            :||| |||  | ||||||
Db       30 SGYYWSWIRQPPGKGLEWIG 49


RESULT 15
US-11-111-688-1
;  Sequence 1, Application US/11111688
;  Publication No. US20060115486A1
;  GENERAL INFORMATION:
;   APPLICANT: Pier, Gerald B
;   APPLICANT: Kelly-Quintos, Casie A
;   APPLICANT: Cavacini, Lisa
;   APPLICANT: Rosner, Marshall R
;   TITLE OF INVENTION: POLY-N-ACETYL GLUCOSAMINE (PNAG/dPNAG)-BINDING
;   TITLE OF INVENTION: PEPTIDES AND METHODS OF USE THEREOF
;   FILE REFERENCE: B0801.70300US01
;   CURRENT APPLICATION NUMBER: US/11/111,688
;   CURRENT FILING DATE: 2005-04-21
;   PRIOR APPLICATION NUMBER: US 60/564,105
;   PRIOR FILING DATE: 2004-04-21
;   NUMBER OF SEQ ID NOS: 61
;   SOFTWARE: PatentIn version 3.3
;  SEQ ID NO 1
;   LENGTH: 124
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-11-111-688-1

Query Match          69.4%;   Score 59;  DB 7;  Length 124;
Best Local Similarity   55.0%;   Pred. No. 0.0037;
Matches   11;  Conservative   1;  Mismatches   8;  Indels   0;  Gaps   0;

Qy        1 TGYXXXXXQSPEKSLEWIG 20
            :||| |||  | ||||||
Db       30 SGYYWSWIRQPPGKGLEWIG 49


Search completed: October 18, 2006, 20:58:14
Job time : 14.3299 secs
```

```
                 GenCore version 5.1.9
        Copyright (c) 1993 - 2006 Biocceleration Ltd.

OM protein - protein search, using sw model

Run on:    October 18, 2006, 19:47:09 ; Search time 294.33 Seconds
                                         (without alignments)
                                         103.758 Million cell updates/sec

Title:           US-10-620-621-1
Perfect score:   85
Sequence:        1 TGYYXXXXQSPEKSLEWIG 20

Scoring table:   BLOSUM62
                 Gapop 10.0 , Gapext 0.5

Searched:        8366291 seqs, 1526956180 residues

Total number of hits satisfying chosen parameters:    8366291

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
                 Maximum Match 100%
                 Listing first 45 summaries

Database : Pending_Patents_AA_Main:*
     1: /EMC_Celerra_SIDS3/ptodata/2/paa/PCTUS_COMB.pep:*
     2: /EMC_Celerra_SIDS3/ptodata/2/paa/US066_COMB.pep:*
     3: /EMC_Celerra_SIDS3/ptodata/2/paa/US073_COMB.pep:*
     4: /EMC_Celerra_SIDS3/ptodata/2/paa/US074_COMB.pep:*
     5: /EMC_Celerra_SIDS3/ptodata/2/paa/US075_COMB.pep:*
     6: /EMC_Celerra_SIDS3/ptodata/2/paa/US076_COMB.pep:*
     7: /EMC_Celerra_SIDS3/ptodata/2/paa/US077_COMB.pep:*
     8: /EMC_Celerra_SIDS3/ptodata/2/paa/US078_COMB.pep:*
     9: /EMC_Celerra_SIDS3/ptodata/2/paa/US079_COMB.pep:*
    10: /EMC_Celerra_SIDS3/ptodata/2/paa/US080_COMB.pep:*
    11: /EMC_Celerra_SIDS3/ptodata/2/paa/US081_COMB.pep:*
    12: /EMC_Celerra_SIDS3/ptodata/2/paa/US082_COMB.pep:*
    13: /EMC_Celerra_SIDS3/ptodata/2/paa/US083_COMB.pep:*
    14: /EMC_Celerra_SIDS3/ptodata/2/paa/US084_COMB.pep:*
    15: /EMC_Celerra_SIDS3/ptodata/2/paa/US085_COMB.pep:*
    16: /EMC_Celerra_SIDS3/ptodata/2/paa/US086_COMB.pep:*
    17: /EMC_Celerra_SIDS3/ptodata/2/paa/US087_COMB.pep:*
    18: /EMC_Celerra_SIDS3/ptodata/2/paa/US088_COMB.pep:*
    19: /EMC_Celerra_SIDS3/ptodata/2/paa/US089_COMB.pep:*
    20: /EMC_Celerra_SIDS3/ptodata/2/paa/US090_COMB.pep:*
    21: /EMC_Celerra_SIDS3/ptodata/2/paa/US091_COMB.pep:*
    22: /EMC_Celerra_SIDS3/ptodata/2/paa/US092_COMB.pep:*
    23: /EMC_Celerra_SIDS3/ptodata/2/paa/US093_COMB.pep:*
    24: /EMC_Celerra_SIDS3/ptodata/2/paa/US094_COMB.pep:*
    25: /EMC_Celerra_SIDS3/ptodata/2/paa/US095_COMB.pep:*
    26: /EMC_Celerra_SIDS3/ptodata/2/paa/US096_COMB.pep:*
    27: /EMC_Celerra_SIDS3/ptodata/2/paa/US097_COMB.pep:*
    28: /EMC_Celerra_SIDS3/ptodata/2/paa/US098_COMB.pep:*
    29: /EMC_Celerra_SIDS3/ptodata/2/paa/US099_COMB.pep:*
    30: /EMC_Celerra_SIDS3/ptodata/2/paa/US100_COMB.pep:*
    31: /EMC_Celerra_SIDS3/ptodata/2/paa/US101_COMB.pep:*
    32: /EMC_Celerra_SIDS3/ptodata/2/paa/US102_COMB.pep:*
    33: /EMC_Celerra_SIDS3/ptodata/2/paa/US103_COMB.pep:*
    34: /EMC_Celerra_SIDS3/ptodata/2/paa/US104_COMB.pep:*
    35: /EMC_Celerra_SIDS3/ptodata/2/paa/US105_COMB.pep:*
    36: /EMC_Celerra_SIDS3/ptodata/2/paa/US106_COMB.pep:*
    37: /EMC_Celerra_SIDS3/ptodata/2/paa/US107_COMB.pep:*
    38: /EMC_Celerra_SIDS3/ptodata/2/paa/US108_COMB.pep:*
    39: /EMC_Celerra_SIDS3/ptodata/2/paa/US109_COMB.pep:*
    40: /EMC_Celerra_SIDS3/ptodata/2/paa/US110_COMB.pep:*
    41: /EMC_Celerra_SIDS3/ptodata/2/paa/US111_COMB.pep:*
    42: /EMC_Celerra_SIDS3/ptodata/2/paa/US112_COMB.pep:*
    43: /EMC_Celerra_SIDS3/ptodata/2/paa/US113_COMB.pep:*
    44: /EMC_Celerra_SIDS3/ptodata/2/paa/US114_COMB.pep:*
    45: /EMC_Celerra_SIDS3/ptodata/2/paa/US600_COMB.pep:*
    46: /EMC_Celerra_SIDS3/ptodata/2/paa/US601_COMB.pep:*
    47: /EMC_Celerra_SIDS3/ptodata/2/paa/US602_COMB.pep:*
    48: /EMC_Celerra_SIDS3/ptodata/2/paa/US603_COMB.pep:*
    49: /EMC_Celerra_SIDS3/ptodata/2/paa/US604_COMB.pep:*
    50: /EMC_Celerra_SIDS3/ptodata/2/paa/US605_COMB.pep:*
    51: /EMC_Celerra_SIDS3/ptodata/2/paa/US606_COMB.pep:*
    52: /EMC_Celerra_SIDS3/ptodata/2/paa/US607_COMB.pep:*
```

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	80	94.1	20	20	PCT-US96-04206-1	Sequence 1, Appli
2	80	94.1	20	36	US-10-620-621-1	Sequence 1, Appli
3	80	94.1	20	37	US-10-758-397-11	Sequence 11, Appl
4	80	94.1	20	37	US-10-758-397A-11	Sequence 11, Appl
5	79	92.9	20	1	PCT-IL02-00148-1	Sequence 1, Appli
6	79	92.9	20	1	PCT-US96-04206-6	Sequence 6, Appli
7	79	92.9	20	34	US-10-468-924-1	Sequence 1, Appli
8	79	92.9	20	34	US-10-468-924A-1	Sequence 1, Appli
9	79	92.9	20	36	US-10-620-621-6	Sequence 6, Appli
10	79	92.9	20	37	US-10-758-397-1	Sequence 1, Appli
11	79	92.9	20	37	US-10-758-397A-1	Sequence 1, Appli
12	79	92.9	103	27	US-09-791-537-11946	Sequence 11946, A
13	79	92.9	105	27	US-09-791-537-82724	Sequence 82724, A
14	79	92.9	111	27	US-09-791-537-14790	Sequence 14790, A
15	79	92.9	112	27	US-09-791-537-14835	Sequence 14835, A
16	79	92.9	115	27	US-09-791-537-14831	Sequence 14831, A
17	79	92.9	118	27	US-09-791-537-149906	Sequence 149906,
18	79	92.9	138	27	US-09-791-537-77301	Sequence 77301, A
19	79	92.9	470	35	US-10-526-741-12	Sequence 12, Appl
20	74	87.1	97	27	US-09-791-537-61187	Sequence 61187, A
21	71	83.5	255	1	PCT-US01-19110-1626	Sequence 1626, Ap
22	71	83.5	255	1	PCT-US02-36496-1626	Sequence 1626, Ap
23	71	83.5	255	28	US-09-880-748-1626	Sequence 1626, Ap
24	71	83.5	255	32	US-10-293-418-1626	Sequence 1626, Ap
25	71	83.5	255	40	US-11-054-515-1626	Sequence 1626, Ap
26	71	83.5	255	42	US-11-266-444-1626	Sequence 1626, Ap
27	71	83.5	255	52	US-60-725-626-1626	Sequence 1626, Ap
28	71	83.5	255	52	US-60-735-988-1626	Sequence 1626, Ap
29	71	83.5	255	52	US-60-776-665-1626	Sequence 1626, Ap
30	71	83.5	467	39	US-10-961-567A-3	Sequence 3, Appli
31	71	83.5	470	39	US-10-961-567A-9	Sequence 9, Appli
32	70	82.4	119	27	US-09-791-537-135207	Sequence 135207,
33	68	80.0	671	42	US-11-202-507A-14	Sequence 14, Appl
34	68	80.0	672	29	US-09-900-766-1	Sequence 1, Appli
35	68	80.0	672	42	US-11-202-507A-7	Sequence 7, Appli
36	67	78.8	117	27	US-09-791-537-129898	Sequence 129898,
37	65	76.5	89	27	US-09-791-537-72370	Sequence 72370, A
38	65	76.5	97	27	US-09-791-537-144799	Sequence 144799,
39	65	76.5	106	27	US-09-791-537-6277	Sequence 6277, Ap
40	65	76.5	115	27	US-09-791-537-102697	Sequence 102697,
41	65	76.5	117	27	US-09-791-537-41128	Sequence 41128, A
42	65	76.5	129	33	US-10-312-316-47	Sequence 47, Appl
43	65	76.5	134	27	US-09-791-537-22034	Sequence 22034, A
44	65	76.5	134	27	US-09-791-537-22035	Sequence 22035, A
45	65	76.5	134	27	US-09-791-537-22040	Sequence 22040, A

ALIGNMENTS

```
RESULT 1
PCT-US96-04206-1
; Sequence 1, Application PC/TUS9604206
; GENERAL INFORMATION:
```

```
Qy    1 TGYYXXXXQSPEKSLEWIG 20
          ||||||||||||||||||
Db    1 TGYYXXXXQSPEKSLEWIG 20
```

RESULT 4
US-10-758-397A-11
; Sequence 11, Application US/10758397A
; GENERAL INFORMATION:
;   APPLICANT: Cohen-Vered, et al., Sharon
;   TITLE OF INVENTION: PARENTERAL FORMULATIONS OF PEPTIDES FOR THE TREATMENT OF SYSTEMIC
;   TITLE OF INVENTION: ERYTHEMATOSUS
;   FILE REFERENCE: 2609/68811-A
;   CURRENT APPLICATION NUMBER: US/10/758,397A
;   CURRENT FILING DATE: 2004-01-14
;   SOFTWARE: PatentIn version 3.1
;   NUMBER OF SEQ ID NOS: 18
;   SEQ ID NO 11
;   LENGTH: 20
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic peptide based on CDR of mouse autoantibody
;   FEATURE:
;   NAME/KEY: MISC_FEATURE
;   LOCATION: (5)..(5)
;   OTHER INFORMATION: X= Met, Ala or Val
;   FEATURE:
;   NAME/KEY: MISC_FEATURE
;   LOCATION: (6)..(6)
;   OTHER INFORMATION: X= Gln, Asp, Glu or Arg
;   FEATURE:
;   NAME/KEY: MISC_FEATURE
;   LOCATION: (7)..(7)
;   OTHER INFORMATION: X= Trp or Ala
;   FEATURE:
;   NAME/KEY: MISC_FEATURE
;   LOCATION: (8)..(8)
;   OTHER INFORMATION: X= Val or Ser
;   FEATURE:
;   NAME/KEY: MISC_FEATURE
;   LOCATION: (9)..(9)
;   OTHER INFORMATION: X= Lys, Glu or Ala
US-10-758-397A-11

```
Query Match             94.1%;   Score 80;  DB 37;   Length 20;
Best Local Similarity  100.0%;   Pred. No. 2.4e-06;
Matches    20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy    1 TGYYXXXXQSPEKSLEWIG 20
          ||||||||||||||||||
Db    1 TGYYXXXXQSPEKSLEWIG 20
```

RESULT 5
PCT-IL02-00148-1
; Sequence 1, Application PC/TIL0200148
; GENERAL INFORMATION:
;   APPLICANT: YEDA Research and Development Co. Ltd
;   APPLICANT: MOZES, Edna
;   TITLE OF INVENTION: PEPTIDES FROM THE 16/6id ANTIBODY FOR TREATING SLE
;   FILE REFERENCE: TEVA-003 PCT
;   CURRENT APPLICATION NUMBER: PCT/IL02/00148
;   CURRENT FILING DATE: 2003-10-15
;   PRIOR APPLICATION NUMBER: IL 141647
;   PRIOR FILING DATE: 2001-02-26
;   NUMBER OF SEQ ID NOS: 30
;   SOFTWARE: PatentIn version 3.1
;   SEQ ID NO 1
;   LENGTH: 20
;   TYPE: PRT
;   ORGANISM: Murine

PCT-IL02-00148-1

```
Query Match             92.9%;   Score 79;  DB 1;   Length 20;
Best Local Similarity   75.0%;   Pred. No. 3.6e-06;
Matches    15;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy    1 TGYYXXXXQSPEKSLEWIG 20
          ||||   |||||||||||
Db    1 TGYYMQWKQSPEKSLEWIG 20
```

RESULT 6
PCT-US96-04206-6
; Sequence 6, Application PC/TUS9604206
; GENERAL INFORMATION:
;   APPLICANT:
;   TITLE OF INVENTION: SYNTHETIC PEPTIDES AND PHARMACEUTICAL
;   TITLE OF INVENTION: COMPOSITIONS COMPRISING THEM FOR THE TREATMENT
;   TITLE OF INVENTION: OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
;   NUMBER OF SEQUENCES: 10
;   COMPUTER READABLE FORM:
;   MEDIUM TYPE: Floppy disk
;   COMPUTER: IBM PC compatible
;   OPERATING SYSTEM: PC-DOS/MS-DOS
;   SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
;   CURRENT APPLICATION DATA:
;   APPLICATION NUMBER: PCT/US96/04206
;   FILING DATE:
;   CLASSIFICATION:
;   PRIOR APPLICATION DATA:
;   APPLICATION NUMBER: IL 113,159
;   FILING DATE: 28-MAR-1995
;   INFORMATION FOR SEQ ID NO: 6:
;   SEQUENCE CHARACTERISTICS:
;   LENGTH: 20 amino acids
;   TYPE: amino acid
;   STRANDEDNESS: single
;   TOPOLOGY: linear
;   MOLECULE TYPE: peptide
PCT-US96-04206-6

```
Query Match             92.9%;   Score 79;  DB 1;   Length 20;
Best Local Similarity   75.0%;   Pred. No. 3.6e-06;
Matches    15;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy    1 TGYYXXXXQSPEKSLEWIG 20
          ||||   |||||||||||
Db    1 TGYYMQWVKQSPEKSLEWIG 20
```

RESULT 7
US-10-468-924-1
; Sequence 1, Application US/10468924
; GENERAL INFORMATION:
;   APPLICANT: MOZES, Edna
;   TITLE OF INVENTION: Synthetic Human Peptides and Pharmaceutical Compositions Compris
;   TITLE OF INVENTION: for the Treatment of Systemic Lupus Erythematosus
;   FILE REFERENCE: TEVA-003 PCT
;   CURRENT APPLICATION NUMBER: US/10/468,924
;   CURRENT FILING DATE: 2003-08-21
;   PRIOR APPLICATION NUMBER: IL 141647
;   PRIOR FILING DATE: 2001-02-26
;   NUMBER OF SEQ ID NOS: 30
;   SOFTWARE: PatentIn version 3.1
;   SEQ ID NO 1
;   LENGTH: 20
;   TYPE: PRT
;   ORGANISM: Murine
US-10-468-924-1

```
Query Match             92.9%;   Score 79;  DB 34;   Length 20;
Best Local Similarity   75.0%;   Pred. No. 3.6e-06;
```

Matches   15;   Conservative   0;   Mismatches   5;   Indels   0;   Gaps   0;

Qy   1 TGYYXXXXQSPEKSLEWIG 20
          |||| ||||||||||
Db   1 TGYYMQWVKQSPEKSLEWIG 20

RESULT 12
US-09-791-537-11946
; Sequence 11946, Application US/09791537
; GENERAL INFORMATION:
; APPLICANT: Bionomix, Inc.
; APPLICANT: Debe, Derek
; APPLICANT: Danzer, Joseph
; TITLE OF INVENTION: THREE DIMENSIONAL STRUCTURES OF PROTEIN FAMILIES AND FAMILY MEMBE
; TITLE OF INVENTION: METHODS OF USE THEREOF
; FILE REFERENCE: 261/210
; CURRENT APPLICATION NUMBER: US/09/791,537
; CURRENT FILING DATE: 2001-02-22
; NUMBER OF SEQ ID NOS: 153055
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 11946
; LENGTH: 103
; TYPE: PRT
; ORGANISM: Mus musculus
US-09-791-537-11946

Query Match   92.9%; Score 79; DB 27; Length 103;
Best Local Similarity   75.0%; Pred. No. 1.7e-05;
Matches   15;   Conservative   0;   Mismatches   5;   Indels   0;   Gaps   0;

Qy   1 TGYYXXXXQSPEKSLEWIG 20
          |||| ||||||||||
Db   49 TGYYMNWVKQSPEKSLEWIG 68

RESULT 13
US-09-791-537-82724
; Sequence 82724, Application US/09791537
; GENERAL INFORMATION:
; APPLICANT: Bionomix, Inc.
; APPLICANT: Debe, Derek
; APPLICANT: Danzer, Joseph
; TITLE OF INVENTION: THREE DIMENSIONAL STRUCTURES OF PROTEIN FAMILIES AND FAMILY MEMBE
; TITLE OF INVENTION: METHODS OF USE THEREOF
; FILE REFERENCE: 261/210
; CURRENT APPLICATION NUMBER: US/09/791,537
; CURRENT FILING DATE: 2001-02-22
; NUMBER OF SEQ ID NOS: 153055
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 82724
; LENGTH: 105
; TYPE: PRT
; ORGANISM: Mus musculus
US-09-791-537-82724

Query Match   92.9%; Score 79; DB 27; Length 105;
Best Local Similarity   75.0%; Pred. No. 1.8e-05;
Matches   15;   Conservative   0;   Mismatches   5;   Indels   0;   Gaps   0;

Qy   1 TGYYXXXXQSPEKSLEWIG 20
          |||| ||||||||||
Db   29 TGYYMHWVKQSPEKSLEWIG 48

RESULT 14
US-09-791-537-14790
; Sequence 14790, Application US/09791537
; GENERAL INFORMATION:
; APPLICANT: Bionomix, Inc.
; APPLICANT: Debe, Derek
; APPLICANT: Danzer, Joseph
; TITLE OF INVENTION: THREE DIMENSIONAL STRUCTURES OF PROTEIN FAMILIES AND FAMILY MEMBE

; TITLE OF INVENTION: METHODS OF USE THEREOF
; FILE REFERENCE: 261/210
; CURRENT APPLICATION NUMBER: US/09/791,537
; CURRENT FILING DATE: 2001-02-22
; NUMBER OF SEQ ID NOS: 153055
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 14790
; LENGTH: 111
; TYPE: PRT
; ORGANISM: Mus musculus
US-09-791-537-14790

Query Match   92.9%; Score 79; DB 27; Length 111;
Best Local Similarity   75.0%; Pred. No. 1.9e-05;
Matches   15;   Conservative   0;   Mismatches   5;   Indels   0;   Gaps   0;

Qy   1 TGYYXXXXQSPEKSLEWIG 20
          |||| ||||||||||
Db   26 TGYYMNWVKQSPEKSLEWIG 45

RESULT 15
US-09-791-537-14835
; Sequence 14835, Application US/09791537
; GENERAL INFORMATION:
; APPLICANT: Bionomix, Inc.
; APPLICANT: Debe, Derek
; APPLICANT: Danzer, Joseph
; TITLE OF INVENTION: THREE DIMENSIONAL STRUCTURES OF PROTEIN FAMILIES AND FAMILY MEMBE
; TITLE OF INVENTION: METHODS OF USE THEREOF
; FILE REFERENCE: 261/210
; CURRENT APPLICATION NUMBER: US/09/791,537
; CURRENT FILING DATE: 2001-02-22
; NUMBER OF SEQ ID NOS: 153055
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 14835
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Mus musculus
US-09-791-537-14835

Query Match   92.9%; Score 79; DB 27; Length 112;
Best Local Similarity   75.0%; Pred. No. 1.9e-05;
Matches   15;   Conservative   0;   Mismatches   5;   Indels   0;   Gaps   0;

Qy   1 TGYYXXXXQSPEKSLEWIG 20
          |||| ||||||||||
Db   27 TGYYMNWVKQSPEKSLEWIG 46

Search completed: October 18, 2006, 20:38:32
Job time : 295.33 secs

November 2005

Published_Applications Nucleic Acid and Published_Applications Amino Acid database searches now generate two sets of results each. The Published_Applications databases have been split into two parts to reduce the amount of time required for their daily updates. This results in more machine time being available for processing searches.

Newly published applications will appear in the Published_Applications_New databases: older published applications make up the Published_Applications_Main databases.

Searches run against Nucleic Acid Published_Applications produce two sets of results, with the extensions **.rnpbm** (Published_Applications_NA_Main) and **.rnpbn** (Published_Applications_NA_New). Searches run against Amino Acid Published_Applications produce two sets of results, with the extensions **.rapbm** (Published_Applications_AA_Main) and **.rapbn** (Published_Applications_AA_New).

US-11-202-507A-14

Query Match   80.0%;   Score 68;   DB 6;   Length 671;
Best Local Similarity   65.0%;   Pred. No. 0.0072;
Matches   13;   Conservative   0;   Mismatches   7;   Indels   0;   Gaps   0;

```
Qy    1 TGYYXXXXQSPEKSLEWIG 20
        |||| |||  ||  |||||
Db   30 TGYYMHWVKQSPGKGLEWIG 49
```

RESULT 13
US-09-900-766-1
; Sequence 1, Application US/09900766
; Publication No. US2003003965A1
; GENERAL INFORMATION:
;   APPLICANT: FORSBERG, GORAN
;   APPLICANT: ERLANDSSON, EVA
;   APPLICANT: ANTONSSON, PER
;   APPLICANT: WALSE, BJORN
;   TITLE OF INVENTION: A NOVEL ENGINEERED SUPERANTIGEN FOR HUMAN THERAPY
;   FILE REFERENCE: P02188US0:10104199
;   CURRENT APPLICATION NUMBER: US/09/900,766
;   CURRENT FILING DATE: 2001-07-06
;   NUMBER OF SEQ ID NOS: 7
;   SOFTWARE: PatentIn version 3.0
;   SEQ ID NO 1
;   LENGTH: 672
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: PEPTIDE
;   LOCATION: (1)..(672)
;   OTHER INFORMATION: Conjugate protein
US-09-900-766-1

Query Match   80.0%;   Score 68;   DB 3;   Length 672;
Best Local Similarity   65.0%;   Pred. No. 0.0072;
Matches   13;   Conservative   0;   Mismatches   7;   Indels   0;   Gaps   0;

```
Qy    1 TGYYXXXXQSPEKSLEWIG 20
        |||| |||  ||  |||||
Db   30 TGYYMHWVKQSPGKGLEWIG 49
```

RESULT 14
US-11-202-507A-7
; Sequence 7, Application US/11202507A
; Publication No. US20060057111A1
; GENERAL INFORMATION:
;   APPLICANT: Hedlund, Gunnar
;   APPLICANT: Forsberg, Goran
;   APPLICANT: Wallen-Ohman, Marie
;   TITLE OF INVENTION: TREATMENT OF HYPERPROLIFERATIVE DISEASE WITH SUPERANTIGENS IN
;   TITLE OF INVENTION: COMBINATION WITH ANOTHER ANTICANCER AGENT
;   FILE REFERENCE: P03024US1
;   CURRENT APPLICATION NUMBER: US/11/202,507A
;   CURRENT FILING DATE: 2005-08-12
;   PRIOR APPLICATION NUMBER: US 60/601,548
;   PRIOR FILING DATE: 2004-08-13
;   NUMBER OF SEQ ID NOS: 16
;   SOFTWARE: PatentIn version 3.3
;   SEQ ID NO 7
;   LENGTH: 672
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Conjugate Protein
;   FEATURE:
;   NAME/KEY: MISC FEATURE
;   LOCATION: (449)..(672)
;   OTHER INFORMATION: Light Chain
US-11-202-507A-7

Query Match   80.0%;   Score 68;   DB 6;   Length 672;
Best Local Similarity   65.0%;   Pred. No. 0.0072;
Matches   13;   Conservative   0;   Mismatches   7;   Indels   0;   Gaps   0;

```
Qy    1 TGYYXXXXQSPEKSLEWIG 20
        |||| |||  ||  |||||
Db   30 TGYYMHWVKQSPGKGLEWIG 49
```

RESULT 15
US-10-312-316-47
; Sequence 47, Application US/10312316
; Publication No. US20040137513A1
; GENERAL INFORMATION:
;   APPLICANT: Genentech, Inc.
;   APPLICANT: Devaux, Brigitte
;   APPLICANT: Hongo, Jo-Anne S.
;   APPLICANT: Presta, Leonard G.
;   APPLICANT: Shelton, David L.
;   TITLE OF INVENTION: AGONIST ANTI-TRK-C MONOCLONAL ANTIBODIES
;   FILE REFERENCE: GENENT.040QPC
;   CURRENT APPLICATION NUMBER: US/10/312,316
;   CURRENT FILING DATE: 2002-12-20
;   PRIOR APPLICATION NUMBER: 60/238,319
;   PRIOR FILING DATE: 2000-10-05
;   NUMBER OF SEQ ID NOS: 89
;   SOFTWARE: FastSEQ for Windows Version 4.0
;   SEQ ID NO 47
;   LENGTH: 129
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-10-312-316-47

Query Match   76.5%;   Score 65;   DB 4;   Length 129;
Best Local Similarity   63.2%;   Pred. No. 0.0045;
Matches   12;   Conservative   0;   Mismatches   7;   Indels   0;   Gaps   0;

```
Qy    2 GYYXXXXQSPEKSLEWIG 20
        |||  ||  ||  |||||
Db   34 GYYWSWIRQHPEKGLEWIG 52
```

Search completed: October 18, 2006, 20:55:48
Job time : 80.3814 secs

; PRIOR FILING DATE: 2000-10-17
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1626
; LENGTH: 255
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-054-515-1626

Query Match   83.5%; Score 71; DB 6; Length 255;
Best Local Similarity 65.0%; Pred. No. 0.00083;
Matches 13; Conservative 1; Mismatches 6; Indels 0; Gaps 0;

Qy   1 TGYYXXXXQSPEKSLEWIG 20
          |||| ||||| ||||||
Db   30 SGYYWSWVRQSPEKGLEWIG 49

RESULT 9
US-11-266-444-1626
; Sequence 1626, Application US/11266444
; Publication No. US20060062789A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind to B Lymphocyte Stimulato
; FILE REFERENCE: PF523P1D1
; CURRENT APPLICATION NUMBER: US/11/266,444
; CURRENT FILING DATE: 2005-11-04
; PRIOR APPLICATION NUMBER: 09/880,746
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1626
; LENGTH: 255
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-266-444-1626

Query Match   83.5%; Score 71; DB 6; Length 255;
Best Local Similarity 65.0%; Pred. No. 0.00083;
Matches 13; Conservative 1; Mismatches 6; Indels 0; Gaps 0;

Qy   1 TGYYXXXXQSPEKSLEWIG 20
          |||| ||||| ||||||
Db   30 SGYYWSWVRQSPEKGLEWIG 49

RESULT 10
US-10-961-567A-3
; Sequence 3, Application US/10961567A
; Publication No. US20050095244A1
; GENERAL INFORMATION:
; APPLICANT: Jure-Kunkel, Maria
; APPLICANT: Hefta, Laura
; APPLICANT: Santoro, Marc
; APPLICANT: Ganguly, Subinay
; TITLE OF INVENTION: FULLY HUMAN ANTIBODIES AGAINST HUMAN 4-1BB
; FILE REFERENCE: 10060 NP
; CURRENT APPLICATION NUMBER: US/10/961,567A
; CURRENT FILING DATE: 2004-10-08
; PRIOR APPLICATION NUMBER: US 60/510193
; PRIOR FILING DATE: 2003-10-10
; NUMBER OF SEQ ID NOS: 9

; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 3
; LENGTH: 467
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: pD17-20H4.9.h4a amino acid sequence
US-10-961-567A-3

Query Match   83.5%; Score 71; DB 5; Length 467;
Best Local Similarity 65.0%; Pred. No. 0.0015;
Matches 13; Conservative 1; Mismatches 6; Indels 0; Gaps 0;

Qy   1 TGYYXXXXQSPEKSLEWIG 20
          |||| ||||| ||||||
Db   49 SGYYWSWIRQSPEKGLEWIG 68

RESULT 11
US-10-961-567A-9
; Sequence 9, Application US/10961567A
; Publication No. US20050095244A1
; GENERAL INFORMATION:
; APPLICANT: Jure-Kunkel, Maria
; APPLICANT: Hefta, Laura
; APPLICANT: Santoro, Marc
; APPLICANT: Ganguly, Subinay
; TITLE OF INVENTION: FULLY HUMAN ANTIBODIES AGAINST HUMAN 4-1BB
; FILE REFERENCE: 10060 NP
; CURRENT APPLICATION NUMBER: US/10/961,567A
; CURRENT FILING DATE: 2004-10-08
; PRIOR APPLICATION NUMBER: US 60/510193
; PRIOR FILING DATE: 2003-10-10
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9
; LENGTH: 470
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: 20H4.9-IgG1 amino acid sequence
US-10-961-567A-9

Query Match   83.5%; Score 71; DB 5; Length 470;
Best Local Similarity 65.0%; Pred. No. 0.0015;
Matches 13; Conservative 1; Mismatches 6; Indels 0; Gaps 0;

Qy   1 TGYYXXXXQSPEKSLEWIG 20
          |||| ||||| ||||||
Db   49 SGYYWSWIRQSPEKGLEWIG 68

RESULT 12
US-11-202-507A-14
; Sequence 14, Application US/11202507A
; Publication No. US20060057111A1
; GENERAL INFORMATION:
; APPLICANT: Hedlund, Gunnar
; APPLICANT: Forsberg, Goran
; APPLICANT: Wallen-Ohman, Marie
; TITLE OF INVENTION: TREATMENT OF HYPERPROLIFERATIVE DISEASE WITH SUPERANTIGENS IN
; TITLE OF INVENTION: COMBINATION WITH ANOTHER ANTICANCER AGENT
; FILE REFERENCE: P03024US1
; CURRENT APPLICATION NUMBER: US/11/202,507A
; CURRENT FILING DATE: 2005-08-12
; PRIOR APPLICATION NUMBER: US 60/601,548
; PRIOR FILING DATE: 2004-08-13
; NUMBER OF SEQ ID NOS: 16
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 14
; LENGTH: 671
; TYPE: PRT
; ORGANISM: Staphylococcus sp

Best Local Similarity 75.0%; Pred. No. 2.7e-06;
Matches   15; Conservative   0; Mismatches   5; Indels   0; Gaps   0;

Qy   1 TGYYXXXXQSPEKSLEWIG 20
           |||| ||||||||||
Db   1 TGYYMQWVKQSPEKSLEWIG 20

RESULT 5
US-10-758-397-1
; Sequence 1, Application US/10758397
; Publication No. US2005008634A1
; GENERAL INFORMATION:
; APPLICANT: Cohen-Vered, et al., Sharon
; TITLE OF INVENTION: PARENTERAL FORMULATIONS OF PEPTIDES FOR THE TREATMENT OF SYSTEMIC
; TITLE OF INVENTION: ERYTHEMATOSUS
; FILE REFERENCE: 2609/68811-A
; CURRENT APPLICATION NUMBER: US/10/758,397
; CURRENT FILING DATE: 2004-01-14
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic peptide based on CDR of mouse autoantibody
US-10-758-397-1

Query Match   92.9%; Score 79; DB 5; Length 20;
Best Local Similarity   75.0%; Pred. No. 2.7e-06;
Matches   15; Conservative   0; Mismatches   5; Indels   0; Gaps   0;

Qy   1 TGYYXXXXQSPEKSLEWIG 20
           |||| ||||||||||
Db   1 TGYYMQWVKQSPEKSLEWIG 20

RESULT 6
US-09-880-748-1626
; Sequence 1626, Application US/09880748
; Publication No. US2003005937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind BLyS
; FILE REFERENCE: PF523
; CURRENT APPLICATION NUMBER: US/09/880,748
; CURRENT FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1626
; LENGTH: 255
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-1626

Query Match   83.5%; Score 71; DB 3; Length 255;
Best Local Similarity   65.0%; Pred. No. 0.00083;
Matches   13; Conservative   1; Mismatches   6; Indels   0; Gaps   0;

Qy   1 TGYYXXXXQSPEKSLEWIG 20
           |||| ||||||||||
Db   30 SGYYWSWVRQSPEKGLEWIG 49

RESULT 7
US-10-293-418-1626
; Sequence 1626, Application US/10293418
; Publication No. US20030223996A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind BLyS
; FILE REFERENCE: PF523P2
; CURRENT APPLICATION NUMBER: US/10/293,418
; CURRENT FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1626
; LENGTH: 255
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-293-418-1626

Query Match   83.5%; Score 71; DB 4; Length 255;
Best Local Similarity   65.0%; Pred. No. 0.00083;
Matches   13; Conservative   1; Mismatches   6; Indels   0; Gaps   0;

Qy   1 TGYYXXXXQSPEKSLEWIG 20
           |||| ||||||||||
Db   30 SGYYWSWVRQSPEKGLEWIG 49

RESULT 8
US-11-054-515-1626
; Sequence 1626, Application US/11054515
; Publication No. US20050255532A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind BLyS
; FILE REFERENCE: PF523P3
; CURRENT APPLICATION NUMBER: US/11/054,515
; CURRENT FILING DATE: 2005-02-10
; PRIOR APPLICATION NUMBER: 60/543,296
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: 60/580,347
; PRIOR FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: 10/293,418
; PRIOR FILING DATE: 2002-11-14
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816